A genetically heterogeneous group of heritable disorders resulting from defects in protein N-glycosylation.
The chemical or biochemical addition of carbohydrate or glycosyl groups to other chemicals, especially peptides or proteins. Glycosyl transferases are used in this biochemical reaction.
Inborn errors of carbohydrate metabolism are genetic disorders that result from enzyme deficiencies or transport defects in the metabolic pathways responsible for breaking down and processing carbohydrates, leading to accumulation of toxic intermediates or energy deficits, and typically presenting with multisystem clinical manifestations.
A group of enzymes that catalyze an intramolecular transfer of a phosphate group. It has been shown in some cases that the enzyme has a functional phosphate group, which can act as the donor. These were previously listed under PHOSPHOTRANSFERASES (EC 2.7.-). (From Enzyme Nomenclature, 1992) EC 5.4.2.
Enzymes that catalyze the transfer of mannose from a nucleoside diphosphate mannose to an acceptor molecule which is frequently another carbohydrate. The group includes EC 2.4.1.32, EC 2.4.1.48, EC 2.4.1.54, and EC 2.4.1.57.
An enzyme that catalyzes the reversible isomerization of D-mannose-6-phosphate to form D-fructose-6-phosphate, an important step in glycolysis. EC 5.3.1.8.
Abnormal increase in skeletal or smooth muscle tone. Skeletal muscle hypertonicity may be associated with PYRAMIDAL TRACT lesions or BASAL GANGLIA DISEASES.
Polysaccharides are complex carbohydrates consisting of long, often branched chains of repeating monosaccharide units joined together by glycosidic bonds, which serve as energy storage molecules (e.g., glycogen), structural components (e.g., cellulose), and molecular recognition sites in various biological systems.
Eicosamethyl octacontanonadecasen-1-o1. Polyprenol found in animal tissues that contains about 20 isoprene residues, the one carrying the alcohol group being saturated.
Any of the enzymatically catalyzed modifications of the individual AMINO ACIDS of PROTEINS, and enzymatic cleavage or crosslinking of peptide chains that occur pre-translationally (on the amino acid component of AMINO ACYL TRNA), co-translationally (during the process of GENETIC TRANSLATION), or after translation is completed (POST-TRANSLATIONAL PROTEIN PROCESSING).
An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.
Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.
Congenital MEGACOLON resulting from the absence of ganglion cells (aganglionosis) in a distal segment of the LARGE INTESTINE. The aganglionic segment is permanently contracted thus causing dilatation proximal to it. In most cases, the aganglionic segment is within the RECTUM and SIGMOID COLON.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form.
Fucose is a deoxyhexose sugar, specifically a L-configuration 6-deoxygalactose, often found as a component of complex carbohydrates called glycans in various glycoproteins and glycolipids within the human body.
Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point.
'Abnormalities, Multiple' is a broad term referring to the presence of two or more structural or functional anomalies in an individual, which may be genetic or environmental in origin, and can affect various systems and organs of the body.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A hexose or fermentable monosaccharide and isomer of glucose from manna, the ash Fraxinus ornus and related plants. (From Grant & Hackh's Chemical Dictionary, 5th ed & Random House Unabridged Dictionary, 2d ed)
Rare, autosomal recessive disorder caused by deficiency of the beta 2 integrin receptors (RECEPTORS, LEUKOCYTE-ADHESION) comprising the CD11/CD18 family of glycoproteins. The syndrome is characterized by abnormal adhesion-dependent functions, especially defective tissue emigration of neutrophils, leading to recurrent infection.
That part of the genome that corresponds to the complete complement of EXONS of an organism or cell.
A stack of flattened vesicles that functions in posttranslational processing and sorting of proteins, receiving them from the rough ENDOPLASMIC RETICULUM and directing them to secretory vesicles, LYSOSOMES, or the CELL MEMBRANE. The movement of proteins takes place by transfer vesicles that bud off from the rough endoplasmic reticulum or Golgi apparatus and fuse with the Golgi, lysosomes or cell membrane. (From Glick, Glossary of Biochemistry and Molecular Biology, 1990)
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The sequence of carbohydrates within POLYSACCHARIDES; GLYCOPROTEINS; and GLYCOLIPIDS.
A characteristic symptom complex.
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
An N-acetylglycosamine containing antiviral antibiotic obtained from Streptomyces lysosuperificus. It is also active against some bacteria and fungi, because it inhibits the glucosylation of proteins. Tunicamycin is used as tool in the study of microbial biosynthetic mechanisms.
Enzymes that catalyze the transfer of glucose from a nucleoside diphosphate glucose to an acceptor molecule which is frequently another carbohydrate. EC 2.4.1.-.
Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis.
Congenital cystic dilatation of the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC). It consists of 2 types: simple Caroli disease is characterized by bile duct dilatation (ectasia) alone; and complex Caroli disease is characterized by bile duct dilatation with extensive hepatic fibrosis and portal hypertension (HYPERTENSION, PORTAL). Benign renal tubular ectasia is associated with both types of Caroli disease.
A class of proteins involved in the transport of molecules via TRANSPORT VESICLES. They perform functions such as binding to the cell membrane, capturing cargo molecules and promoting the assembly of CLATHRIN. The majority of adaptor proteins exist as multi-subunit complexes, however monomeric varieties have also been found.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Malformations of organs or body parts during development in utero.
Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.
Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
An infant during the first month after birth.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A system of cisternae in the CYTOPLASM of many cells. In places the endoplasmic reticulum is continuous with the plasma membrane (CELL MEMBRANE) or outer membrane of the nuclear envelope. If the outer surfaces of the endoplasmic reticulum membranes are coated with ribosomes, the endoplasmic reticulum is said to be rough-surfaced (ENDOPLASMIC RETICULUM, ROUGH); otherwise it is said to be smooth-surfaced (ENDOPLASMIC RETICULUM, SMOOTH). (King & Stansfield, A Dictionary of Genetics, 4th ed)
Persistent and disabling ANXIETY.
Biochemical identification of mutational changes in a nucleotide sequence.
Genes that influence the PHENOTYPE only in the homozygous state.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Those disorders that have a disturbance in mood as their predominant feature.
The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.
A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed)
Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
An individual in which both alleles at a given locus are identical.
Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility.
Categorical classification of MENTAL DISORDERS based on criteria sets with defining features. It is produced by the American Psychiatric Association. (DSM-IV, page xxii)
Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.
An amidohydrolase that removes intact asparagine-linked oligosaccharide chains from glycoproteins. It requires the presence of more than two amino-acid residues in the substrate for activity. This enzyme was previously listed as EC 3.2.2.18.
Different forms of a protein that may be produced from different GENES, or from the same gene by ALTERNATIVE SPLICING.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight.
Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.
Enzymes that catalyze the transfer of glycosyl groups to an acceptor. Most often another carbohydrate molecule acts as an acceptor, but inorganic phosphate can also act as an acceptor, such as in the case of PHOSPHORYLASES. Some of the enzymes in this group also catalyze hydrolysis, which can be regarded as transfer of a glycosyl group from the donor to water. Subclasses include the HEXOSYLTRANSFERASES; PENTOSYLTRANSFERASES; SIALYLTRANSFERASES; and those transferring other glycosyl groups. EC 2.4.
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis.
The characteristic 3-dimensional shape of a carbohydrate.
The systematic study of the structure and function of the complete set of glycans (the glycome) produced in a single organism and identification of all the genes that encode glycoproteins.
Enzymes that catalyze the transfer of N-acetylglucosamine from a nucleoside diphosphate N-acetylglucosamine to an acceptor molecule which is frequently another carbohydrate. EC 2.4.1.-.
An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.

Alteration of mannose transport in fibroblasts from type I carbohydrate deficient glycoprotein syndrome patients. (1/113)

The aim of the present study was to explore how mannose enters fibroblasts derived from a panel of children suffering from different subtypes of type I carbohydrate deficient glycoprotein syndrome: seven carbohydrate deficient glycoprotein syndrome subtype Ia (phosphomannomutase deficiency), two carbohydrate deficient glycoprotein syndrome subtype Ib (phosphomannose isomerase deficiency) and two carbohydrate deficient glycoprotein syndrome subtype Ix (not identified deficiency). We showed that a specific mannose transport system exists in all the cells tested but has different characteristics with respect to carbohydrate deficient glycoprotein syndrome subtypes. Subtype Ia fibroblasts presented a mannose uptake equivalent or higher (maximum 1.6-fold) than control cells with a D-[2-3H]-mannose incorporation in nascent N-glycoproteins decreased up to 7-fold. Compared to control cells, the mannose uptake was greatly stimulated in subtype Ib (4.0-fold), due to lower Kuptake and higher Vmax values. Subtype Ib cells showed an increased incorporation of D-[2-3H]-mannose into nascent N-glycoproteins. Subtype Ix fibroblasts presented an intermediary status with mannose uptake equivalent to the control but with an increased incorporation of D-[2-3H]-mannose in nascent N-glycoproteins. All together, our results demonstrate quantitative and/or qualitative modifications in mannose transport of all carbohydrate deficient glycoprotein syndrome fibroblasts in comparison to control cells, with a relative homogeneity within a considered subtype of carbohydrate deficient glycoprotein syndrome. These results are consistent with the possible use of mannose as a therapeutic agent in carbohydrate deficient glycoprotein syndrome Ib and Ix.  (+info)

A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic. (2/113)

Carbohydrate-deficient glycoprotein syndrome (CDGS) represents a class of genetic diseases characterized by abnormal N-linked glycosylation. CDGS patients show a large number of glycoprotein abnormalities resulting in dysmorphy, encephalopathy, and other organ disorders. The majority of CDGSs described to date are related to an impaired biosynthesis of dolichyl pyrophosphate-linked Glc3Man9GlcNAc2 in the endoplasmic reticulum. Recently, we identified in four related patients a novel type of CDGS characterized by an accumulation of dolichyl pyrophosphate-linked Man9GlcNAc2. Elaborating on the analogy of this finding with the phenotype of alg5 and alg6 Saccharomyces cerevisiae strains, we have cloned and analyzed the human orthologs to the ALG5 dolichyl phosphate glucosyltransferase and ALG6 dolichyl pyrophosphate Man9GlcNAc2 alpha1,3-glucosyltransferase in four novel CDGS patients. Although ALG5 was not altered in the patients, a C-->T transition was detected in ALG6 cDNA of all four CDGS patients. The mutation cosegregated with the disease in a Mendelian recessive manner. Expression of the human ALG5 and ALG6 cDNA could partially complement the respective S. cerevisiae alg5 and alg6 deficiency. By contrast, the mutant ALG6 cDNA of CDGS patients failed to revert the hypoglycosylation observed in alg6 yeasts, thereby proving a functional relationship between the alanine to valine substitution introduced by the C-->T transition and the CDGS phenotype. The mutation in the ALG6 alpha1,3-glucosyltransferase gene defines an additional type of CDGS, which we propose to refer to as CDGS type-Ic.  (+info)

Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2. (3/113)

Seven mutant forms of human phosphomannomutase 2 were produced in Escherichia coli and purified. These mutants had a Vmax of 0.2-50% of the wild enzyme and were unstable. The least active protein (R141H) bears a very frequent mutation, which has never been found in the homozygous state whereas the second least active protein (D188G) corresponds to a mutation associated with a particularly severe phenotype. We conclude that total lack of phosphomannomutase 2 is incompatible with life. Another conclusion is that the elevated residual phosphomannomutase activity found in fibroblasts of some patients is contributed by their mutated phosphomannomutase 2.  (+info)

Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. (4/113)

BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms. This alteration could be similar to that present in patients with carbohydrate-deficient glycoprotein syndrome type 1 (CDG1). We thus compared the alterations of N-glycans present in patients with alcoholism and patients with CDG1. METHODS: The N-glycans of serum glycoproteins were compared in sera of patients with alcoholism, patients with CDG1, and controls by two-dimensional electrophoresis, neuraminidase, peptide:N-glycosidase F, and endoglycosidase F2 treatments. A specific antibody directed against the amino acid sequence surrounding the N-432 N-glycosylation site of transferrin was prepared (SZ-350 antibody). RESULTS: In patients with alcoholism, the abnormal transferrin and alpha(1)-antitrypsin isoforms were devoid of a variable number of entire N-glycan moieties and were identical with those present in CDG1. In the serum of patients with alcoholism, this finding was less pronounced than in CDG1. In contrast to CDG1, there was no decrease in clusterin or serum amyloid P in patients with alcoholism. The SZ-350 antibody recognized only transferrin isoforms with one or no N-glycan moieties. CONCLUSION: Antibodies directed against specific N-glycosylation sites of glycoproteins could be useful for developing more specific immunochemical tests for the diagnosis of chronic alcohol abuse.  (+info)

A new type of carbohydrate-deficient glycoprotein syndrome due to a decreased import of GDP-fucose into the golgi. (5/113)

The fucosylation of glycoproteins was found to be deficient in a patient with a clinical phenotype resembling that of leukocyte adhesion deficiency type II (LAD II). While in LAD II hypofucosylation of glycoconjugates is secondary to an impaired synthesis of GDP-fucose due to a deficiency of the GDP-D-mannose-4, 6-dehydratase, synthesis of GDP-fucose was normal in our patient (Korner, C., Linnebank, M., Koch, H., Harms, E., von Figura, K., and Marquardt, T. (1999) J. Leukoc. Biol., in press). Import of GDP-fucose into Golgi-enriched vesicles was composed of a saturable, high affinity and a nonsaturable component. In our patient the saturable high affinity import of GDP-fucose was deficient, while import of UDP-galactose and the activity of GDPase, which generates the nucleoside phosphate required for antiport of GDP-fucose, were normal. Addition of L-fucose to the medium of fibroblasts restored the fucosylation of glycoproteins. We propose that this new form of carbohydrate-deficient glycoprotein syndrome is caused by impaired import of GDP-fucose into the Golgi.  (+info)

Determination of carbohydrate-deficient transferrin separated by lectin affinity chromatography for detecting chronic alcohol abuse. (6/113)

Carbohydrate-deficient transferrin (CDT) has been established as a valuable biological marker for detecting chronic alcohol abuse. To improve the diagnostic efficiency, we studied new CDT determination procedures involving the use of lectin affinity chromatography with Allomyrina dichotoma agglutinin (allo A) and Trichosanthes japonica agglutinin I (TJA-I) to isolate the CDT isoforms CDT-allo A and CDT-TJA, respectively. These procedures, based on detection of the CDT-allo A and CDT-TJA isoforms in sera, showed high sensitivity (100% and 98%, respectively) and high specificity (93% and 85%, respectively). These results demonstrate that the new procedures involving the use of lectin affinity chromatography are more useful for isolating markers in the CDT test than the conventional charge-based separation method.  (+info)

beta-Trace protein in human cerebrospinal fluid: a diagnostic marker for N-glycosylation defects in brain. (7/113)

As carbohydrate-deficient glycoprotein syndromes (CDGS) are multisystemic disorders with impaired central nervous function in nearly all cases, we tested isoforms of beta-trace protein (beta TP), a 'brain-type' glycosylated protein in cerebrospinal fluid (CSF) of nine patients with the characteristic CDGS type I pattern of serum transferrin. Whereas the serum transferrin pattern did not discriminate between the various subtypes of CDGS type I (CDGS type Ia, type Ic, and patients with unknown defect), beta TP isoforms of CDGS type Ia patients differed from that of the other CDGS type I patients. The percentage of abnormal beta TP isoforms correlated with the severity of the neurological symptoms. Furthermore, two patients are described, who illustrate that abnormal protein N-glycosylation can occur restricted to either the 'peripheral' serum or the central nervous system compartment. This is the first report presenting evidence for an N-glycosylation defect restricted to the brain. Testing beta TP isoforms is a useful tool to detect protein N-glycosylation disorders in the central nervous system.  (+info)

Glycosylation defects corrected by the changes in GDPmannose level. (8/113)

GDPMan is a key substrate in glycoprotein formation. This is especially true for lower eukaryotes where, in addition to the involvement in N-glycan biosynthesis and GPI-anchor formation, GDPMan takes part in the process which is unique for yeast and fungi i.e. O-mannosylation. Several lines of evidence have been presented that the level of GDPMan affects the process occurring in the Golgi compartment i.e. the elongation of outer mannose chain of glycoproteins in Saccharomyces cerevisiae. Results from our laboratory indicate that the availability of GDPMan affects also the early steps of glycoprotein formation ascribed to the endoplasmic reticulum, i.e. assembly of the dolichol-linked oligosaccharide as well as mannosyl-phosphodolichol (MPD) formation. The biochemical basis of carbohydrate deficient glycoprotein syndrome, a severe neurological disorder related to the GDPMan deficiency, is also discussed.  (+info)

Congenital Disorders of Glycosylation (CDG) are a group of genetic disorders that affect the body's ability to add sugar molecules (glycans) to proteins and lipids. This process, known as glycosylation, is essential for the proper functioning of many cellular processes, including protein folding, trafficking, and signaling.

CDG can be caused by mutations in genes that are involved in the synthesis or transport of glycans. These genetic defects can lead to abnormal glycosylation patterns, which can result in a wide range of clinical manifestations, including developmental delay, intellectual disability, seizures, movement disorders, hypotonia, coagulation abnormalities, and multi-organ involvement.

CDG are typically classified into two main types: type I CDG, which involves defects in the synthesis of the lipid-linked oligosaccharide precursor used for N-glycosylation, and type II CDG, which involves defects in the processing and transfer of glycans to proteins.

The diagnosis of CDG is often based on clinical features, laboratory tests, and genetic analysis. Treatment is typically supportive and multidisciplinary, focusing on addressing specific symptoms and improving quality of life. In some cases, dietary modifications or supplementation with mannose or other sugars may be beneficial.

Glycosylation is the enzymatic process of adding a sugar group, or glycan, to a protein, lipid, or other organic molecule. This post-translational modification plays a crucial role in modulating various biological functions, such as protein stability, trafficking, and ligand binding. The structure and composition of the attached glycans can significantly influence the functional properties of the modified molecule, contributing to cell-cell recognition, signal transduction, and immune response regulation. Abnormal glycosylation patterns have been implicated in several disease states, including cancer, diabetes, and neurodegenerative disorders.

Inborn errors of carbohydrate metabolism refer to genetic disorders that affect the body's ability to break down and process carbohydrates, which are sugars and starches that provide energy for the body. These disorders are caused by defects in enzymes or transport proteins that play a critical role in the metabolic pathways involved in carbohydrate metabolism.

There are several types of inborn errors of carbohydrate metabolism, including:

1. Galactosemia: This disorder affects the body's ability to metabolize the sugar galactose, which is found in milk and other dairy products. It is caused by a deficiency of the enzyme galactose-1-phosphate uridylyltransferase.
2. Glycogen storage diseases: These disorders affect the body's ability to store and break down glycogen, which is a complex carbohydrate that serves as a source of energy for the body. There are several types of glycogen storage diseases, each caused by a deficiency in a different enzyme involved in glycogen metabolism.
3. Hereditary fructose intolerance: This disorder affects the body's ability to metabolize the sugar fructose, which is found in fruits and sweeteners. It is caused by a deficiency of the enzyme aldolase B.
4. Pentose phosphate pathway disorders: These disorders affect the body's ability to metabolize certain sugars and generate energy through the pentose phosphate pathway. They are caused by defects in enzymes involved in this pathway.

Symptoms of inborn errors of carbohydrate metabolism can vary widely depending on the specific disorder and its severity. Treatment typically involves dietary restrictions, supplementation with necessary enzymes or cofactors, and management of complications. In some cases, enzyme replacement therapy or even organ transplantation may be considered.

Mannosyltransferases are a group of enzymes that catalyze the transfer of mannose (a type of sugar) to specific acceptor molecules during the process of glycosylation. Glycosylation is the attachment of carbohydrate groups, or glycans, to proteins and lipids, which plays a crucial role in various biological processes such as protein folding, quality control, trafficking, and cell-cell recognition.

In particular, mannosyltransferases are involved in the addition of mannose residues to the core oligosaccharide structure of N-linked glycans in the endoplasmic reticulum (ER) and Golgi apparatus of eukaryotic cells. These enzymes use a donor substrate, typically dolichol-phosphate-mannose (DPM), to add mannose molecules to the acceptor substrate, which is an asparagine residue within a growing glycan chain.

There are several classes of mannosyltransferases, each responsible for adding mannose to specific positions within the glycan structure. Defects in these enzymes can lead to various genetic disorders known as congenital disorders of glycosylation (CDG), which can affect multiple organ systems and result in a wide range of clinical manifestations.

Mannose-6-Phosphate Isomerase (MPI) is an enzyme that catalyzes the interconversion between mannose-6-phosphate and fructose-6-phosphate, which are both key metabolites in the glycolysis and gluconeogenesis pathways. This enzyme plays a crucial role in maintaining the balance between these two metabolic pathways, allowing cells to either break down or synthesize glucose depending on their energy needs.

The gene that encodes for MPI is called MPI1 and is located on chromosome 4 in humans. Defects in this gene can lead to a rare genetic disorder known as Mannose-6-Phosphate Isomerase Deficiency or Congenital Disorder of Glycosylation Type IIm, which is characterized by developmental delay, intellectual disability, seizures, and various other neurological symptoms.

Muscle hypertonia is a term used to describe an increased tone or tension in the muscles, which can be caused by various medical conditions. This state leads to a reduced ability to stretch the muscle fully, and it may interfere with normal movement. The two main types of muscle hypertonia are spasticity and rigidity.

1. Spasticity: It is a velocity-dependent increase in muscle tone, which means that the resistance to passive movement increases as the speed of the movement increases. This type of hypertonia is often associated with upper motor neuron lesions, such as those caused by stroke, spinal cord injury, or multiple sclerosis.
2. Rigidity: It is a constant and non-velocity dependent increase in muscle tone, meaning that the resistance to passive movement remains consistent regardless of the speed. This type of hypertonia can be seen in conditions like Parkinson's disease.

It is essential to diagnose and manage muscle hypertonia effectively to prevent complications such as contractures, pain, and decreased functional abilities. Treatment options may include physical therapy, medications (like antispasticity agents), orthoses, or surgical interventions in severe cases.

Polysaccharides are complex carbohydrates consisting of long chains of monosaccharide units (simple sugars) bonded together by glycosidic linkages. They can be classified based on the type of monosaccharides and the nature of the bonds that connect them.

Polysaccharides have various functions in living organisms. For example, starch and glycogen serve as energy storage molecules in plants and animals, respectively. Cellulose provides structural support in plants, while chitin is a key component of fungal cell walls and arthropod exoskeletons.

Some polysaccharides also have important roles in the human body, such as being part of the extracellular matrix (e.g., hyaluronic acid) or acting as blood group antigens (e.g., ABO blood group substances).

Dolichol is a type of lipid molecule that is involved in the process of protein glycosylation within the endoplasmic reticulum of eukaryotic cells. Glycosylation is the attachment of sugar molecules to proteins, and it plays a crucial role in various biological processes such as protein folding, trafficking, and cell-cell recognition.

Dolichols are long-chain polyisoprenoid alcohols that serve as carriers for the sugars during glycosylation. They consist of a hydrophobic tail made up of many isoprene units and a hydrophilic head group. The dolichol molecule is first activated by the addition of a diphosphate group to its terminal end, forming dolichyl pyrophosphate.

The sugars that will be attached to the protein are then transferred from their nucleotide sugar donors onto the dolichyl pyrophosphate carrier, creating a dolichol-linked oligosaccharide. This oligosaccharide is then transferred en bloc to the target protein in a process called "oligosaccharyltransferase" (OST) reaction.

Defects in dolichol biosynthesis or function can lead to various genetic disorders, such as congenital disorders of glycosylation (CDG), which are characterized by abnormal protein glycosylation and a wide range of clinical manifestations, including developmental delay, neurological impairment, and multi-systemic involvement.

Translational protein modification refers to the covalent alteration of a protein during or shortly after its synthesis on the ribosome. This process is an essential mechanism for regulating protein function and can have a significant impact on various aspects of protein biology, including protein stability, localization, activity, and interaction with other molecules.

During translation, as the nascent polypeptide chain emerges from the ribosome, it can be modified by enzymes that recognize specific sequences or motifs within the protein. These modifications can include the addition of chemical groups such as phosphate, acetyl, methyl, ubiquitin, or SUMO (small ubiquitin-like modifier) groups, among others.

Examples of translational protein modifications include:

1. N-terminal acetylation: The addition of an acetyl group to the alpha-amino group of the first amino acid in a polypeptide chain. This modification can affect protein stability and localization.
2. Ubiquitination: The covalent attachment of ubiquitin molecules to lysine residues within a protein, which can target it for degradation by the proteasome or regulate its activity and interactions with other proteins.
3. SUMOylation: The addition of a SUMO group to a lysine residue in a protein, which can modulate protein-protein interactions, subcellular localization, and stability.
4. Phosphorylation: The addition of a phosphate group to serine, threonine, or tyrosine residues within a protein, which can regulate enzymatic activity, protein-protein interactions, and signal transduction pathways.

Translational protein modifications play crucial roles in various cellular processes, including gene expression regulation, DNA repair, cell cycle control, stress response, and apoptosis. Dysregulation of these modifications has been implicated in numerous diseases, such as cancer, neurodegenerative disorders, and metabolic disorders.

Transferrin is a glycoprotein that plays a crucial role in the transport and homeostasis of iron in the body. It's produced mainly in the liver and has the ability to bind two ferric (Fe3+) ions in its N-lobe and C-lobe, thus creating transferrin saturation.

This protein is essential for delivering iron to cells while preventing the harmful effects of free iron, which can catalyze the formation of reactive oxygen species through Fenton reactions. Transferrin interacts with specific transferrin receptors on the surface of cells, particularly in erythroid precursors and brain endothelial cells, to facilitate iron uptake via receptor-mediated endocytosis.

In addition to its role in iron transport, transferrin also has antimicrobial properties due to its ability to sequester free iron, making it less available for bacterial growth and survival. Transferrin levels can be used as a clinical marker of iron status, with decreased levels indicating iron deficiency anemia and increased levels potentially signaling inflammation or liver disease.

Inborn errors of metabolism (IEM) refer to a group of genetic disorders caused by defects in enzymes or transporters that play a role in the body's metabolic processes. These disorders result in the accumulation or deficiency of specific chemicals within the body, which can lead to various clinical manifestations, such as developmental delay, intellectual disability, seizures, organ damage, and in some cases, death.

Examples of IEM include phenylketonuria (PKU), maple syrup urine disease (MSUD), galactosemia, and glycogen storage diseases, among many others. These disorders are typically inherited in an autosomal recessive manner, meaning that an affected individual has two copies of the mutated gene, one from each parent.

Early diagnosis and management of IEM are crucial to prevent or minimize complications and improve outcomes. Treatment options may include dietary modifications, supplementation with missing enzymes or cofactors, medication, and in some cases, stem cell transplantation or gene therapy.

Hirschsprung disease is a gastrointestinal disorder that affects the large intestine, specifically the section known as the colon. This condition is congenital, meaning it is present at birth. It occurs due to the absence of ganglion cells (nerve cells) in the bowel's muscular wall, which are responsible for coordinating muscle contractions that move food through the digestive tract.

The affected segment of the colon cannot relax and propel the contents within it, leading to various symptoms such as constipation, intestinal obstruction, or even bowel perforation in severe cases. Common diagnostic methods include rectal suction biopsy, anorectal manometry, and contrast enema studies. Treatment typically involves surgical removal of the aganglionic segment and reattachment of the normal colon to the anus (known as a pull-through procedure).

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Oligosaccharides are complex carbohydrates composed of relatively small numbers (3-10) of monosaccharide units joined together by glycosidic linkages. They occur naturally in foods such as milk, fruits, vegetables, and legumes. In the body, oligosaccharides play important roles in various biological processes, including cell recognition, signaling, and protection against pathogens.

There are several types of oligosaccharides, classified based on their structures and functions. Some common examples include:

1. Disaccharides: These consist of two monosaccharide units, such as sucrose (glucose + fructose), lactose (glucose + galactose), and maltose (glucose + glucose).
2. Trisaccharides: These contain three monosaccharide units, like maltotriose (glucose + glucose + glucose) and raffinose (galactose + glucose + fructose).
3. Oligosaccharides found in human milk: Human milk contains unique oligosaccharides that serve as prebiotics, promoting the growth of beneficial bacteria in the gut. These oligosaccharides also help protect infants from pathogens by acting as decoy receptors and inhibiting bacterial adhesion to intestinal cells.
4. N-linked and O-linked glycans: These are oligosaccharides attached to proteins in the body, playing crucial roles in protein folding, stability, and function.
5. Plant-derived oligosaccharides: Fructooligosaccharides (FOS) and galactooligosaccharides (GOS) are examples of plant-derived oligosaccharides that serve as prebiotics, promoting the growth of beneficial gut bacteria.

Overall, oligosaccharides have significant impacts on human health and disease, particularly in relation to gastrointestinal function, immunity, and inflammation.

Fucose is a type of sugar molecule that is often found in complex carbohydrates known as glycans, which are attached to many proteins and lipids in the body. It is a hexose sugar, meaning it contains six carbon atoms, and is a type of L-sugar, which means that it rotates plane-polarized light in a counterclockwise direction.

Fucose is often found at the ends of glycan chains and plays important roles in various biological processes, including cell recognition, signaling, and interaction. It is also a component of some blood group antigens and is involved in the development and function of the immune system. Abnormalities in fucosylation (the addition of fucose to glycans) have been implicated in various diseases, including cancer, inflammation, and neurological disorders.

Isoelectric focusing (IEF) is a technique used in electrophoresis, which is a method for separating proteins or other molecules based on their electrical charges. In IEF, a mixture of ampholytes (molecules that can carry both positive and negative charges) is used to create a pH gradient within a gel matrix. When an electric field is applied, the proteins or molecules migrate through the gel until they reach the point in the gradient where their net charge is zero, known as their isoelectric point (pI). At this point, they focus into a sharp band and stop moving, resulting in a highly resolved separation of the different components based on their pI. This technique is widely used in protein research for applications such as protein identification, characterization, and purification.

'Abnormalities, Multiple' is a broad term that refers to the presence of two or more structural or functional anomalies in an individual. These abnormalities can be present at birth (congenital) or can develop later in life (acquired). They can affect various organs and systems of the body and can vary greatly in severity and impact on a person's health and well-being.

Multiple abnormalities can occur due to genetic factors, environmental influences, or a combination of both. Chromosomal abnormalities, gene mutations, exposure to teratogens (substances that cause birth defects), and maternal infections during pregnancy are some of the common causes of multiple congenital abnormalities.

Examples of multiple congenital abnormalities include Down syndrome, Turner syndrome, and VATER/VACTERL association. Acquired multiple abnormalities can result from conditions such as trauma, infection, degenerative diseases, or cancer.

The medical evaluation and management of individuals with multiple abnormalities depend on the specific abnormalities present and their impact on the individual's health and functioning. A multidisciplinary team of healthcare professionals is often involved in the care of these individuals to address their complex needs.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Mannose is a simple sugar (monosaccharide) that is similar in structure to glucose. It is a hexose, meaning it contains six carbon atoms. Mannose is a stereoisomer of glucose, meaning it has the same chemical formula but a different structural arrangement of its atoms.

Mannose is not as commonly found in foods as other simple sugars, but it can be found in some fruits, such as cranberries, blueberries, and peaches, as well as in certain vegetables, like sweet potatoes and turnips. It is also found in some dietary fibers, such as those found in beans and whole grains.

In the body, mannose can be metabolized and used for energy, but it is also an important component of various glycoproteins and glycolipids, which are molecules that play critical roles in many biological processes, including cell recognition, signaling, and adhesion.

Mannose has been studied as a potential therapeutic agent for various medical conditions, including urinary tract infections (UTIs), because it can inhibit the attachment of certain bacteria to the cells lining the urinary tract. Additionally, mannose-binding lectins have been investigated for their potential role in the immune response to viral and bacterial infections.

Leukocyte Adhesion Deficiency Syndrome (LAD) is a group of rare inherited disorders that affect the ability of white blood cells, specifically neutrophils, to adhere to and migrate into tissues, particularly those involved in immune responses. This results in recurrent bacterial and fungal infections starting in infancy.

There are three types of LAD, each caused by different genetic mutations:

1. LAD I: This is the most common and severe form, caused by a deficiency in the CD18 protein which is crucial for neutrophil adhesion. Symptoms include delayed separation of the umbilical cord, severe periodontal disease, and recurrent skin, lung and gastrointestinal infections.

2. LAD II: Also known as congenital disorder of glycosylation, type Ib, it is caused by a deficiency in the enzyme glucosyltransferase, leading to abnormal sugar chains on cell surfaces. Symptoms are similar to LAD I but less severe, and also include mental retardation and impaired growth.

3. LAD III: This is the least common form, caused by a defect in the integrin-linked kinase (ILK) gene. It results in a more complex phenotype with muscular and cardiac abnormalities, in addition to immune dysfunction.

Treatment typically involves prophylactic antibiotics, granulocyte-colony stimulating factor (G-CSF) to increase neutrophil counts, and sometimes bone marrow transplantation.

The exome is the part of the genome that contains all the protein-coding regions. It represents less than 2% of the human genome but accounts for about 85% of disease-causing mutations. Exome sequencing, therefore, is a cost-effective and efficient method to identify genetic variants associated with various diseases, including cancer, neurological disorders, and inherited genetic conditions.

The Golgi apparatus, also known as the Golgi complex or simply the Golgi, is a membrane-bound organelle found in the cytoplasm of most eukaryotic cells. It plays a crucial role in the processing, sorting, and packaging of proteins and lipids for transport to their final destinations within the cell or for secretion outside the cell.

The Golgi apparatus consists of a series of flattened, disc-shaped sacs called cisternae, which are stacked together in a parallel arrangement. These stacks are often interconnected by tubular structures called tubules or vesicles. The Golgi apparatus has two main faces: the cis face, which is closest to the endoplasmic reticulum (ER) and receives proteins and lipids directly from the ER; and the trans face, which is responsible for sorting and dispatching these molecules to their final destinations.

The Golgi apparatus performs several essential functions in the cell:

1. Protein processing: After proteins are synthesized in the ER, they are transported to the cis face of the Golgi apparatus, where they undergo various post-translational modifications, such as glycosylation (the addition of sugar molecules) and sulfation. These modifications help determine the protein's final structure, function, and targeting.
2. Lipid modification: The Golgi apparatus also modifies lipids by adding or removing different functional groups, which can influence their properties and localization within the cell.
3. Protein sorting and packaging: Once proteins and lipids have been processed, they are sorted and packaged into vesicles at the trans face of the Golgi apparatus. These vesicles then transport their cargo to various destinations, such as lysosomes, plasma membrane, or extracellular space.
4. Intracellular transport: The Golgi apparatus serves as a central hub for intracellular trafficking, coordinating the movement of vesicles and other transport carriers between different organelles and cellular compartments.
5. Cell-cell communication: Some proteins that are processed and packaged in the Golgi apparatus are destined for secretion, playing crucial roles in cell-cell communication and maintaining tissue homeostasis.

In summary, the Golgi apparatus is a vital organelle involved in various cellular processes, including post-translational modification, sorting, packaging, and intracellular transport of proteins and lipids. Its proper functioning is essential for maintaining cellular homeostasis and overall organismal health.

Glycoproteins are complex proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. These glycans are linked to the protein through asparagine residues (N-linked) or serine/threonine residues (O-linked). Glycoproteins play crucial roles in various biological processes, including cell recognition, cell-cell interactions, cell adhesion, and signal transduction. They are widely distributed in nature and can be found on the outer surface of cell membranes, in extracellular fluids, and as components of the extracellular matrix. The structure and composition of glycoproteins can vary significantly depending on their function and location within an organism.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

A "carbohydrate sequence" refers to the specific arrangement or order of monosaccharides (simple sugars) that make up a carbohydrate molecule, such as a polysaccharide or an oligosaccharide. Carbohydrates are often composed of repeating units of monosaccharides, and the sequence in which these units are arranged can have important implications for the function and properties of the carbohydrate.

For example, in glycoproteins (proteins that contain carbohydrate chains), the specific carbohydrate sequence can affect how the protein is processed and targeted within the cell, as well as its stability and activity. Similarly, in complex carbohydrates like starch or cellulose, the sequence of glucose units can determine whether the molecule is branched or unbranched, which can have implications for its digestibility and other properties.

Therefore, understanding the carbohydrate sequence is an important aspect of studying carbohydrate structure and function in biology and medicine.

A syndrome, in medical terms, is a set of symptoms that collectively indicate or characterize a disease, disorder, or underlying pathological process. It's essentially a collection of signs and/or symptoms that frequently occur together and can suggest a particular cause or condition, even though the exact physiological mechanisms might not be fully understood.

For example, Down syndrome is characterized by specific physical features, cognitive delays, and other developmental issues resulting from an extra copy of chromosome 21. Similarly, metabolic syndromes like diabetes mellitus type 2 involve a group of risk factors such as obesity, high blood pressure, high blood sugar, and abnormal cholesterol or triglyceride levels that collectively increase the risk of heart disease, stroke, and diabetes.

It's important to note that a syndrome is not a specific diagnosis; rather, it's a pattern of symptoms that can help guide further diagnostic evaluation and management.

Bipolar disorder, also known as manic-depressive illness, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). When you become depressed, you may feel sad or hopeless and lose interest or pleasure in most activities. When your mood shifts to mania or hypomania (a less severe form of mania), you may feel euphoric, full of energy, or unusually irritable. These mood swings can significantly affect your job, school, relationships, and overall quality of life.

Bipolar disorder is typically characterized by the presence of one or more manic or hypomanic episodes, often accompanied by depressive episodes. The episodes may be separated by periods of normal mood, but in some cases, a person may experience rapid cycling between mania and depression.

There are several types of bipolar disorder, including:

* Bipolar I Disorder: This type is characterized by the occurrence of at least one manic episode, which may be preceded or followed by hypomanic or major depressive episodes.
* Bipolar II Disorder: This type involves the presence of at least one major depressive episode and at least one hypomanic episode, but no manic episodes.
* Cyclothymic Disorder: This type is characterized by numerous periods of hypomania and depression that are not severe enough to meet the criteria for a full manic or depressive episode.
* Other Specified and Unspecified Bipolar and Related Disorders: These categories include bipolar disorders that do not fit the criteria for any of the other types.

The exact cause of bipolar disorder is unknown, but it appears to be related to a combination of genetic, environmental, and neurochemical factors. Treatment typically involves a combination of medication, psychotherapy, and lifestyle changes to help manage symptoms and prevent relapses.

Tunicamycin is not a medical condition or disease, but rather a bacterial antibiotic and a research tool used in biochemistry and cell biology. It is produced by certain species of bacteria, including Streptomyces lysosuperificus and Streptomyces chartreusis.

Tunicamycin works by inhibiting the enzyme that catalyzes the first step in the biosynthesis of N-linked glycoproteins, which are complex carbohydrates that are attached to proteins during their synthesis. This leads to the accumulation of misfolded proteins and endoplasmic reticulum (ER) stress, which can ultimately result in cell death.

In medical research, tunicamycin is often used to study the role of N-linked glycoproteins in various biological processes, including protein folding, quality control, and trafficking. It has also been explored as a potential therapeutic agent for cancer and other diseases, although its use as a drug is limited by its toxicity to normal cells.

Glucosyltransferases (GTs) are a group of enzymes that catalyze the transfer of a glucose molecule from an activated donor to an acceptor molecule, resulting in the formation of a glycosidic bond. These enzymes play crucial roles in various biological processes, including the biosynthesis of complex carbohydrates, cell wall synthesis, and protein glycosylation. In some cases, GTs can also contribute to bacterial pathogenesis by facilitating the attachment of bacteria to host tissues through the formation of glucans, which are polymers of glucose molecules.

GTs can be classified into several families based on their sequence similarities and catalytic mechanisms. The donor substrates for GTs are typically activated sugars such as UDP-glucose, TDP-glucose, or GDP-glucose, which serve as the source of the glucose moiety that is transferred to the acceptor molecule. The acceptor can be a wide range of molecules, including other sugars, proteins, lipids, or small molecules.

In the context of human health and disease, GTs have been implicated in various pathological conditions, such as cancer, inflammation, and microbial infections. For example, some GTs can modify proteins on the surface of cancer cells, leading to increased cell proliferation, migration, and invasion. Additionally, GTs can contribute to bacterial resistance to antibiotics by modifying the structure of bacterial cell walls or by producing biofilms that protect bacteria from host immune responses and antimicrobial agents.

Overall, Glucosyltransferases are essential enzymes involved in various biological processes, and their dysregulation has been associated with several human diseases. Therefore, understanding the structure, function, and regulation of GTs is crucial for developing novel therapeutic strategies to target these enzymes and treat related pathological conditions.

Fibroblasts are specialized cells that play a critical role in the body's immune response and wound healing process. They are responsible for producing and maintaining the extracellular matrix (ECM), which is the non-cellular component present within all tissues and organs, providing structural support and biochemical signals for surrounding cells.

Fibroblasts produce various ECM proteins such as collagens, elastin, fibronectin, and laminins, forming a complex network of fibers that give tissues their strength and flexibility. They also help in the regulation of tissue homeostasis by controlling the turnover of ECM components through the process of remodeling.

In response to injury or infection, fibroblasts become activated and start to proliferate rapidly, migrating towards the site of damage. Here, they participate in the inflammatory response, releasing cytokines and chemokines that attract immune cells to the area. Additionally, they deposit new ECM components to help repair the damaged tissue and restore its functionality.

Dysregulation of fibroblast activity has been implicated in several pathological conditions, including fibrosis (excessive scarring), cancer (where they can contribute to tumor growth and progression), and autoimmune diseases (such as rheumatoid arthritis).

Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) is a type of mass spectrometry that is used to analyze large biomolecules such as proteins and peptides. In this technique, the sample is mixed with a matrix compound, which absorbs laser energy and helps to vaporize and ionize the analyte molecules.

The matrix-analyte mixture is then placed on a target plate and hit with a laser beam, causing the matrix and analyte molecules to desorb from the plate and become ionized. The ions are then accelerated through an electric field and into a mass analyzer, which separates them based on their mass-to-charge ratio.

The separated ions are then detected and recorded as a mass spectrum, which can be used to identify and quantify the analyte molecules present in the sample. MALDI-MS is particularly useful for the analysis of complex biological samples, such as tissue extracts or biological fluids, because it allows for the detection and identification of individual components within those mixtures.

Caroli disease is a rare genetic disorder that affects the liver and bile ducts. It is characterized by abnormal dilations or sac-like structures in the intrahepatic bile ducts, which are the ducts that carry bile from the liver to the gallbladder and small intestine. These dilations can lead to recurrent cholangitis (inflammation of the bile ducts), stone formation, and liver damage.

Caroli disease is usually diagnosed in childhood or early adulthood, and it can be associated with other congenital anomalies such as polycystic kidney disease. The exact cause of Caroli disease is not fully understood, but it is believed to be inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the abnormal gene, one from each parent, to develop the condition.

Treatment for Caroli disease may include antibiotics to manage cholangitis, endoscopic procedures to remove stones or dilate strictures, and surgery to bypass or remove affected bile ducts. In severe cases, liver transplantation may be necessary. Regular monitoring of liver function and surveillance for complications are essential in the management of this condition.

Adaptor proteins play a crucial role in vesicular transport, which is the process by which materials are transported within cells in membrane-bound sacs called vesicles. These adaptor proteins serve as a bridge between vesicle membranes and cytoskeletal elements or other cellular structures, facilitating the movement of vesicles throughout the cell.

There are several different types of adaptor proteins involved in vesicular transport, each with specific functions and localizations within the cell. Some examples include:

1. Clathrin Adaptor Protein Complex (AP-1, AP-2, AP-3, AP-4): These complexes are responsible for recruiting clathrin to membranes during vesicle formation, which helps to shape and stabilize the vesicle. They also play a role in sorting cargo into specific vesicles.

2. Coat Protein Complex I (COPI): This complex is involved in the transport of proteins between the endoplasmic reticulum (ER) and the Golgi apparatus, as well as within the Golgi itself. COPI-coated vesicles are formed by the assembly of coatomer proteins around the membrane, which helps to deform the membrane into a vesicle shape.

3. Coat Protein Complex II (COPII): This complex is involved in the transport of proteins from the ER to the Golgi apparatus. COPII-coated vesicles are formed by the assembly of Sar1, Sec23/24, and Sec13/31 proteins around the membrane, which helps to select cargo and form a vesicle.

4. BAR (Bin/Amphiphysin/Rvs) Domain Proteins: These proteins are involved in shaping and stabilizing membranes during vesicle formation. They can sense and curve membranes, recruiting other proteins to help form the vesicle.

5. SNARE Proteins: While not strictly adaptor proteins, SNAREs play a critical role in vesicle fusion by forming complexes that bring the vesicle and target membrane together. These complexes provide the energy required for membrane fusion, allowing for the release of cargo into the target compartment.

Overall, adaptor proteins are essential components of the cellular machinery that regulates intracellular trafficking. They help to select cargo, deform membranes, and facilitate vesicle formation, ensuring that proteins and lipids reach their correct destinations within the cell.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

Congenital abnormalities, also known as birth defects, are structural or functional anomalies that are present at birth. These abnormalities can develop at any point during fetal development, and they can affect any part of the body. They can be caused by genetic factors, environmental influences, or a combination of both.

Congenital abnormalities can range from mild to severe and may include structural defects such as heart defects, neural tube defects, and cleft lip and palate, as well as functional defects such as intellectual disabilities and sensory impairments. Some congenital abnormalities may be visible at birth, while others may not become apparent until later in life.

In some cases, congenital abnormalities may be detected through prenatal testing, such as ultrasound or amniocentesis. In other cases, they may not be diagnosed until after the baby is born. Treatment for congenital abnormalities varies depending on the type and severity of the defect, and may include surgery, therapy, medication, or a combination of these approaches.

Inborn genetic diseases, also known as inherited genetic disorders, are conditions caused by abnormalities in an individual's DNA that are present at conception. These abnormalities can include mutations, deletions, or rearrangements of genes or chromosomes. In many cases, these genetic changes are inherited from one or both parents and may be passed down through families.

Inborn genetic diseases can affect any part of the body and can cause a wide range of symptoms, which can vary in severity depending on the specific disorder. Some genetic disorders are caused by mutations in a single gene, while others are caused by changes in multiple genes or chromosomes. In some cases, environmental factors may also contribute to the development of these conditions.

Examples of inborn genetic diseases include cystic fibrosis, sickle cell anemia, Huntington's disease, Duchenne muscular dystrophy, and Down syndrome. These conditions can have significant impacts on an individual's health and quality of life, and many require ongoing medical management and treatment. In some cases, genetic counseling and testing may be recommended for individuals with a family history of a particular genetic disorder to help them make informed decisions about their reproductive options.

A mental disorder is a syndrome characterized by clinically significant disturbance in an individual's cognition, emotion regulation, or behavior. It's associated with distress and/or impaired functioning in social, occupational, or other important areas of life, often leading to a decrease in quality of life. These disorders are typically persistent and can be severe and disabling. They may be related to factors such as genetics, early childhood experiences, or trauma. Examples include depression, anxiety disorders, bipolar disorder, schizophrenia, and personality disorders. It's important to note that a diagnosis should be made by a qualified mental health professional.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

The endoplasmic reticulum (ER) is a network of interconnected tubules and sacs that are present in the cytoplasm of eukaryotic cells. It is a continuous membranous organelle that plays a crucial role in the synthesis, folding, modification, and transport of proteins and lipids.

The ER has two main types: rough endoplasmic reticulum (RER) and smooth endoplasmic reticulum (SER). RER is covered with ribosomes, which give it a rough appearance, and is responsible for protein synthesis. On the other hand, SER lacks ribosomes and is involved in lipid synthesis, drug detoxification, calcium homeostasis, and steroid hormone production.

In summary, the endoplasmic reticulum is a vital organelle that functions in various cellular processes, including protein and lipid metabolism, calcium regulation, and detoxification.

Anxiety disorders are a category of mental health disorders characterized by feelings of excessive and persistent worry, fear, or anxiety that interfere with daily activities. They include several different types of disorders, such as:

1. Generalized Anxiety Disorder (GAD): This is characterized by chronic and exaggerated worry and tension, even when there is little or nothing to provoke it.
2. Panic Disorder: This is characterized by recurring unexpected panic attacks and fear of experiencing more panic attacks.
3. Social Anxiety Disorder (SAD): Also known as social phobia, this is characterized by excessive fear, anxiety, or avoidance of social situations due to feelings of embarrassment, self-consciousness, and concern about being judged or viewed negatively by others.
4. Phobias: These are intense, irrational fears of certain objects, places, or situations. When a person with a phobia encounters the object or situation they fear, they may experience panic attacks or other severe anxiety responses.
5. Agoraphobia: This is a fear of being in places where it may be difficult to escape or get help if one has a panic attack or other embarrassing or incapacitating symptoms.
6. Separation Anxiety Disorder (SAD): This is characterized by excessive anxiety about separation from home or from people to whom the individual has a strong emotional attachment (such as a parent, sibling, or partner).
7. Selective Mutism: This is a disorder where a child becomes mute in certain situations, such as at school, but can speak normally at home or with close family members.

These disorders are treatable with a combination of medication and psychotherapy (cognitive-behavioral therapy, exposure therapy). It's important to seek professional help if you suspect that you or someone you know may have an anxiety disorder.

DNA Mutational Analysis is a laboratory test used to identify genetic variations or changes (mutations) in the DNA sequence of a gene. This type of analysis can be used to diagnose genetic disorders, predict the risk of developing certain diseases, determine the most effective treatment for cancer, or assess the likelihood of passing on an inherited condition to offspring.

The test involves extracting DNA from a patient's sample (such as blood, saliva, or tissue), amplifying specific regions of interest using polymerase chain reaction (PCR), and then sequencing those regions to determine the precise order of nucleotide bases in the DNA molecule. The resulting sequence is then compared to reference sequences to identify any variations or mutations that may be present.

DNA Mutational Analysis can detect a wide range of genetic changes, including single-nucleotide polymorphisms (SNPs), insertions, deletions, duplications, and rearrangements. The test is often used in conjunction with other diagnostic tests and clinical evaluations to provide a comprehensive assessment of a patient's genetic profile.

It is important to note that not all mutations are pathogenic or associated with disease, and the interpretation of DNA Mutational Analysis results requires careful consideration of the patient's medical history, family history, and other relevant factors.

Recessive genes refer to the alleles (versions of a gene) that will only be expressed when an individual has two copies of that particular allele, one inherited from each parent. If an individual inherits one recessive allele and one dominant allele for a particular gene, the dominant allele will be expressed and the recessive allele will have no effect on the individual's phenotype (observable traits).

Recessive genes can still play a role in determining an individual's genetic makeup and can be passed down through generations even if they are not expressed. If two carriers of a recessive gene have children, there is a 25% chance that their offspring will inherit two copies of the recessive allele and exhibit the associated recessive trait.

Examples of genetic disorders caused by recessive genes include cystic fibrosis, sickle cell anemia, and albinism.

Membrane proteins are a type of protein that are embedded in the lipid bilayer of biological membranes, such as the plasma membrane of cells or the inner membrane of mitochondria. These proteins play crucial roles in various cellular processes, including:

1. Cell-cell recognition and signaling
2. Transport of molecules across the membrane (selective permeability)
3. Enzymatic reactions at the membrane surface
4. Energy transduction and conversion
5. Mechanosensation and signal transduction

Membrane proteins can be classified into two main categories: integral membrane proteins, which are permanently associated with the lipid bilayer, and peripheral membrane proteins, which are temporarily or loosely attached to the membrane surface. Integral membrane proteins can further be divided into three subcategories based on their topology:

1. Transmembrane proteins, which span the entire width of the lipid bilayer with one or more alpha-helices or beta-barrels.
2. Lipid-anchored proteins, which are covalently attached to lipids in the membrane via a glycosylphosphatidylinositol (GPI) anchor or other lipid modifications.
3. Monotopic proteins, which are partially embedded in the membrane and have one or more domains exposed to either side of the bilayer.

Membrane proteins are essential for maintaining cellular homeostasis and are targets for various therapeutic interventions, including drug development and gene therapy. However, their structural complexity and hydrophobicity make them challenging to study using traditional biochemical methods, requiring specialized techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and single-particle cryo-electron microscopy (cryo-EM).

Mood disorders are a category of mental health disorders characterized by significant and persistent changes in mood, affect, and emotional state. These disorders can cause disturbances in normal functioning and significantly impair an individual's ability to carry out their daily activities. The two primary types of mood disorders are depressive disorders (such as major depressive disorder or persistent depressive disorder) and bipolar disorders (which include bipolar I disorder, bipolar II disorder, and cyclothymic disorder).

Depressive disorders involve prolonged periods of low mood, sadness, hopelessness, and a lack of interest in activities. Individuals with these disorders may also experience changes in sleep patterns, appetite, energy levels, concentration, and self-esteem. In severe cases, they might have thoughts of death or suicide.

Bipolar disorders involve alternating episodes of mania (or hypomania) and depression. During a manic episode, individuals may feel extremely elated, energetic, or irritable, with racing thoughts, rapid speech, and impulsive behavior. They might engage in risky activities, have decreased sleep needs, and display poor judgment. In contrast, depressive episodes involve the same symptoms as depressive disorders.

Mood disorders can be caused by a combination of genetic, biological, environmental, and psychological factors. Proper diagnosis and treatment, which may include psychotherapy, medication, or a combination of both, are essential for managing these conditions and improving quality of life.

I must clarify that the term "pedigree" is not typically used in medical definitions. Instead, it is often employed in genetics and breeding, where it refers to the recorded ancestry of an individual or a family, tracing the inheritance of specific traits or diseases. In human genetics, a pedigree can help illustrate the pattern of genetic inheritance in families over multiple generations. However, it is not a medical term with a specific clinical definition.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

CHO cells, or Chinese Hamster Ovary cells, are a type of immortalized cell line that are commonly used in scientific research and biotechnology. They were originally derived from the ovaries of a female Chinese hamster (Cricetulus griseus) in the 1950s.

CHO cells have several characteristics that make them useful for laboratory experiments. They can grow and divide indefinitely under appropriate conditions, which allows researchers to culture large quantities of them for study. Additionally, CHO cells are capable of expressing high levels of recombinant proteins, making them a popular choice for the production of therapeutic drugs, vaccines, and other biologics.

In particular, CHO cells have become a workhorse in the field of biotherapeutics, with many approved monoclonal antibody-based therapies being produced using these cells. The ability to genetically modify CHO cells through various methods has further expanded their utility in research and industrial applications.

It is important to note that while CHO cells are widely used in scientific research, they may not always accurately represent human cell behavior or respond to drugs and other compounds in the same way as human cells do. Therefore, results obtained using CHO cells should be validated in more relevant systems when possible.

A missense mutation is a type of point mutation in which a single nucleotide change results in the substitution of a different amino acid in the protein that is encoded by the affected gene. This occurs when the altered codon (a sequence of three nucleotides that corresponds to a specific amino acid) specifies a different amino acid than the original one. The function and/or stability of the resulting protein may be affected, depending on the type and location of the missense mutation. Missense mutations can have various effects, ranging from benign to severe, depending on the importance of the changed amino acid for the protein's structure or function.

Intellectual disability (ID) is a term used when there are significant limitations in both intellectual functioning and adaptive behavior, which covers many everyday social and practical skills. This disability originates before the age of 18.

Intellectual functioning, also known as intelligence, refers to general mental capacity, such as learning, reasoning, problem-solving, and other cognitive skills. Adaptive behavior includes skills needed for day-to-day life, such as communication, self-care, social skills, safety judgement, and basic academic skills.

Intellectual disability is characterized by below-average intelligence or mental ability and a lack of skills necessary for day-to-day living. It can be mild, moderate, severe, or profound, depending on the degree of limitation in intellectual functioning and adaptive behavior.

It's important to note that people with intellectual disabilities have unique strengths and limitations, just like everyone else. With appropriate support and education, they can lead fulfilling lives and contribute to their communities in many ways.

Asparagine is an organic compound that is classified as a naturally occurring amino acid. It contains an amino group, a carboxylic acid group, and a side chain consisting of a single carbon atom bonded to a nitrogen atom, making it a neutral amino acid. Asparagine is encoded by the genetic codon AAU or AAC in the DNA sequence.

In the human body, asparagine plays important roles in various biological processes, including serving as a building block for proteins and participating in the synthesis of other amino acids. It can also act as a neurotransmitter and is involved in the regulation of cellular metabolism. Asparagine can be found in many foods, particularly in high-protein sources such as meat, fish, eggs, and dairy products.

A homozygote is an individual who has inherited the same allele (version of a gene) from both parents and therefore possesses two identical copies of that allele at a specific genetic locus. This can result in either having two dominant alleles (homozygous dominant) or two recessive alleles (homozygous recessive). In contrast, a heterozygote has inherited different alleles from each parent for a particular gene.

The term "homozygote" is used in genetics to describe the genetic makeup of an individual at a specific locus on their chromosomes. Homozygosity can play a significant role in determining an individual's phenotype (observable traits), as having two identical alleles can strengthen the expression of certain characteristics compared to having just one dominant and one recessive allele.

Post-translational protein processing refers to the modifications and changes that proteins undergo after their synthesis on ribosomes, which are complex molecular machines responsible for protein synthesis. These modifications occur through various biochemical processes and play a crucial role in determining the final structure, function, and stability of the protein.

The process begins with the translation of messenger RNA (mRNA) into a linear polypeptide chain, which is then subjected to several post-translational modifications. These modifications can include:

1. Proteolytic cleavage: The removal of specific segments or domains from the polypeptide chain by proteases, resulting in the formation of mature, functional protein subunits.
2. Chemical modifications: Addition or modification of chemical groups to the side chains of amino acids, such as phosphorylation (addition of a phosphate group), glycosylation (addition of sugar moieties), methylation (addition of a methyl group), acetylation (addition of an acetyl group), and ubiquitination (addition of a ubiquitin protein).
3. Disulfide bond formation: The oxidation of specific cysteine residues within the polypeptide chain, leading to the formation of disulfide bonds between them. This process helps stabilize the three-dimensional structure of proteins, particularly in extracellular environments.
4. Folding and assembly: The acquisition of a specific three-dimensional conformation by the polypeptide chain, which is essential for its function. Chaperone proteins assist in this process to ensure proper folding and prevent aggregation.
5. Protein targeting: The directed transport of proteins to their appropriate cellular locations, such as the nucleus, mitochondria, endoplasmic reticulum, or plasma membrane. This is often facilitated by specific signal sequences within the protein that are recognized and bound by transport machinery.

Collectively, these post-translational modifications contribute to the functional diversity of proteins in living organisms, allowing them to perform a wide range of cellular processes, including signaling, catalysis, regulation, and structural support.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a publication of the American Psychiatric Association (APA) that provides diagnostic criteria for mental disorders. It is widely used by mental health professionals in the United States and around the world to diagnose and classify mental health conditions.

The DSM includes detailed descriptions of symptoms, clinical examples, and specific criteria for each disorder, which are intended to facilitate accurate diagnosis and improve communication among mental health professionals. The manual is regularly updated to reflect current research and clinical practice, with the most recent edition being the DSM-5, published in 2013.

It's important to note that while the DSM is a valuable tool for mental health professionals, it is not without controversy. Some critics argue that the manual medicalizes normal human experiences and that its categories may be too broad or overlapping. Nonetheless, it remains an essential resource for clinicians, researchers, and policymakers in the field of mental health.

High-performance liquid chromatography (HPLC) is a type of chromatography that separates and analyzes compounds based on their interactions with a stationary phase and a mobile phase under high pressure. The mobile phase, which can be a gas or liquid, carries the sample mixture through a column containing the stationary phase.

In HPLC, the mobile phase is a liquid, and it is pumped through the column at high pressures (up to several hundred atmospheres) to achieve faster separation times and better resolution than other types of liquid chromatography. The stationary phase can be a solid or a liquid supported on a solid, and it interacts differently with each component in the sample mixture, causing them to separate as they travel through the column.

HPLC is widely used in analytical chemistry, pharmaceuticals, biotechnology, and other fields to separate, identify, and quantify compounds present in complex mixtures. It can be used to analyze a wide range of substances, including drugs, hormones, vitamins, pigments, flavors, and pollutants. HPLC is also used in the preparation of pure samples for further study or use.

Protein isoforms are different forms or variants of a protein that are produced from a single gene through the process of alternative splicing, where different exons (or parts of exons) are included in the mature mRNA molecule. This results in the production of multiple, slightly different proteins that share a common core structure but have distinct sequences and functions. Protein isoforms can also arise from genetic variations such as single nucleotide polymorphisms or mutations that alter the protein-coding sequence of a gene. These differences in protein sequence can affect the stability, localization, activity, or interaction partners of the protein isoform, leading to functional diversity and specialization within cells and organisms.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

Glycopeptides are a class of antibiotics that are characterized by their complex chemical structure, which includes both peptide and carbohydrate components. These antibiotics are produced naturally by certain types of bacteria and are effective against a range of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

The glycopeptide antibiotics work by binding to the bacterial cell wall precursor, preventing the cross-linking of peptidoglycan chains that is necessary for the formation of a strong and rigid cell wall. This leads to the death of the bacteria.

Examples of glycopeptides include vancomycin, teicoplanin, and dalbavancin. While these antibiotics have been used successfully for many years, their use is often limited due to concerns about the emergence of resistance and potential toxicity.

Major Depressive Disorder (MDD), also simply referred to as depression, is a serious mental health condition characterized by the presence of one or more major depressive episodes. A major depressive episode is a period of at least two weeks during which an individual experiences a severely depressed mood and/or loss of interest or pleasure in nearly all activities, accompanied by at least four additional symptoms such as significant changes in appetite or weight, sleep disturbances, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive guilt, difficulty thinking, concentrating, or making decisions, and recurrent thoughts of death or suicide.

MDD can significantly impair an individual's ability to function in daily life, and it is associated with increased risks of suicide, substance abuse, and other mental health disorders. The exact cause of MDD is not fully understood, but it is believed to result from a complex interplay of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of psychotherapy (such as cognitive-behavioral therapy) and medication (such as selective serotonin reuptake inhibitors or tricyclic antidepressants).

Glycosyltransferases are a group of enzymes that play a crucial role in the synthesis of glycoconjugates, which are complex carbohydrate structures found on the surface of cells and in various biological fluids. These enzymes catalyze the transfer of a sugar moiety from an activated donor molecule to an acceptor molecule, resulting in the formation of a glycosidic bond.

The donor molecule is typically a nucleotide sugar, such as UDP-glucose or CMP-sialic acid, which provides the energy required for the transfer reaction. The acceptor molecule can be a wide range of substrates, including proteins, lipids, and other carbohydrates.

Glycosyltransferases are highly specific in their activity, with each enzyme recognizing a particular donor and acceptor pair. This specificity allows for the precise regulation of glycan structures, which have been shown to play important roles in various biological processes, including cell recognition, signaling, and adhesion.

Defects in glycosyltransferase function can lead to a variety of genetic disorders, such as congenital disorders of glycosylation (CDG), which are characterized by abnormal glycan structures and a wide range of clinical manifestations, including developmental delay, neurological impairment, and multi-organ dysfunction.

Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity is a neurodevelopmental disorder that affects both children and adults. The condition is characterized by symptoms including:

1. Difficulty paying attention or staying focused on a single task
2. Impulsivity, or acting without thinking
3. Hyperactivity, or excessive fidgeting, restlessness, or talking

In order to be diagnosed with ADHD with hyperactivity, an individual must exhibit these symptoms to a degree that is developmentally inappropriate and interferes with their daily functioning. Additionally, the symptoms must have been present for at least six months and be present in multiple settings (e.g., at home, school, work).

It's important to note that ADHD can manifest differently in different people, and some individuals may experience predominantly inattentive or impulsive symptoms rather than hyperactive ones. However, when the hyperactive component is prominent, it is referred to as ADHD with hyperactivity.

Effective treatments for ADHD with hyperactivity include a combination of medication (such as stimulants) and behavioral therapy. With appropriate treatment, individuals with ADHD can learn to manage their symptoms and lead successful, fulfilling lives.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

A depressive disorder is a mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest or pleasure in activities. It can also include changes in sleep, appetite, energy levels, concentration, and self-esteem, as well as thoughts of death or suicide. Depressive disorders can vary in severity and duration, with some people experiencing mild and occasional symptoms, while others may have severe and chronic symptoms that interfere with their ability to function in daily life.

There are several types of depressive disorders, including major depressive disorder (MDD), persistent depressive disorder (PDD), and postpartum depression. MDD is characterized by symptoms that interfere significantly with a person's ability to function and last for at least two weeks, while PDD involves chronic low-grade depression that lasts for two years or more. Postpartum depression occurs in women after childbirth and can range from mild to severe.

Depressive disorders are thought to be caused by a combination of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of medication, psychotherapy (talk therapy), and lifestyle changes.

DNA Sequence Analysis is the systematic determination of the order of nucleotides in a DNA molecule. It is a critical component of modern molecular biology, genetics, and genetic engineering. The process involves determining the exact order of the four nucleotide bases - adenine (A), guanine (G), cytosine (C), and thymine (T) - in a DNA molecule or fragment. This information is used in various applications such as identifying gene mutations, studying evolutionary relationships, developing molecular markers for breeding, and diagnosing genetic diseases.

The process of DNA Sequence Analysis typically involves several steps, including DNA extraction, PCR amplification (if necessary), purification, sequencing reaction, and electrophoresis. The resulting data is then analyzed using specialized software to determine the exact sequence of nucleotides.

In recent years, high-throughput DNA sequencing technologies have revolutionized the field of genomics, enabling the rapid and cost-effective sequencing of entire genomes. This has led to an explosion of genomic data and new insights into the genetic basis of many diseases and traits.

Carbohydrate conformation refers to the three-dimensional shape and structure of a carbohydrate molecule. Carbohydrates, also known as sugars, can exist in various conformational states, which are determined by the rotation of their component bonds and the spatial arrangement of their functional groups.

The conformation of a carbohydrate molecule can have significant implications for its biological activity and recognition by other molecules, such as enzymes or antibodies. Factors that can influence carbohydrate conformation include the presence of intramolecular hydrogen bonds, steric effects, and intermolecular interactions with solvent molecules or other solutes.

In some cases, the conformation of a carbohydrate may be stabilized by the formation of cyclic structures, in which the hydroxyl group at one end of the molecule forms a covalent bond with the carbonyl carbon at the other end, creating a ring structure. The most common cyclic carbohydrates are monosaccharides, such as glucose and fructose, which can exist in various conformational isomers known as anomers.

Understanding the conformation of carbohydrate molecules is important for elucidating their biological functions and developing strategies for targeting them with drugs or other therapeutic agents.

Glycomics is the study of the glycome, which refers to the complete set of carbohydrates or sugars (glycans) found on the surface of cells and in various biological fluids. Glycomics encompasses the identification, characterization, and functional analysis of these complex carbohydrate structures and their interactions with other molecules, such as proteins and lipids.

Glycans play crucial roles in many biological processes, including cell-cell recognition, signaling, immune response, development, and disease progression. The study of glycomics has implications for understanding the molecular basis of diseases like cancer, diabetes, and infectious disorders, as well as for developing novel diagnostic tools and therapeutic strategies.

N-Acetylglucosaminyltransferases (GlcNAc transferases) are a group of enzymes that play a crucial role in the post-translational modification of proteins by adding N-acetylglucosamine (GlcNAc) to specific amino acids in a protein sequence. These enzymes catalyze the transfer of GlcNAc from a donor molecule, typically UDP-GlcNAc, to acceptor proteins, which can be other glycoproteins or proteins without any prior glycosylation.

The addition of N-acetylglucosamine by these enzymes is an essential step in the formation of complex carbohydrate structures called N-linked glycans, which are attached to asparagine residues within the protein sequence. The process of adding GlcNAc can occur in different ways, leading to various types of N-glycan structures, such as oligomannose, hybrid, and complex types.

There are several classes of N-Acetylglucosaminyltransferases (GnTs) based on their substrate specificity and the type of glycosidic linkage they form:

1. GnT I (MGAT1): Transfers GlcNAc to the α1,6 position of the mannose residue in the chitobiose core of N-linked glycans, initiating the formation of complex-type structures.
2. GnT II (MGAT2): Adds a second GlcNAc residue to the β1,4 position of the mannose residue at the non-reducing end of the chitobiose core, forming bi-antennary N-glycans.
3. GnT III (MGAT3): Transfers GlcNAc to the β1,4 position of the mannose residue in the chitobiose core, creating a branching point for further glycosylation and leading to tri- or tetra-antennary N-glycans.
4. GnT IV (MGAT4): Adds GlcNAc to the β1,4 position of the mannose residue at the non-reducing end of antennae, forming multi-branched complex-type structures.
5. GnT V (MGAT5): Transfers GlcNAc to the β1,6 position of the mannose residue in the chitobiose core, leading to hybrid and complex-type N-glycans with bisecting GlcNAc.
6. GnT VI (MGAT6): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
7. GnT VII (MGAT7): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
8. GnT VIII (MGAT8): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
9. GnT IX (MGAT9): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
10. GnT X (MGAT10): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
11. GnT XI (MGAT11): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
12. GnT XII (MGAT12): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
13. GnT XIII (MGAT13): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
14. GnT XIV (MGAT14): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
15. GnT XV (MGAT15): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
16. GnT XVI (MGAT16): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
17. GnT XVII (MGAT17): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
18. GnT XVIII (MGAT18): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
19. GnT XIX (MGAT19): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
20. GnT XX (MGAT20): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
21. GnT XXI (MGAT21): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
22. GnT XXII (MGAT22): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
23. GnT XXIII (MGAT23): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
24. GnT XXIV (MGAT24): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
25. GnT XXV (MGAT25): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
26. GnT XXVI (MGAT26): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
27. GnT XXVII (MGAT27): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
28. GnT XXVIII (MGAT28): Adds GlcNAc to the α1,3 position of the mannose residue at the non-reducing end of antennae, forming a-linked poly-N-acetyllactosamine structures.
29. GnT XXIX (MGAT29): Transfers GlcNAc to the β1,6 position of the N-acetylglucosamine residue in complex-type N-glycans, forming i-antigen structures.
30. GnT XXX (MG

Obsessive-Compulsive Disorder (OCD) is a mental health disorder characterized by the presence of obsessions and compulsions. Obsessions are recurrent and persistent thoughts, urges, or images that are intrusive, unwanted, and often distressing. Compulsions are repetitive behaviors or mental acts that an individual feels driven to perform in response to an obsession or according to rigid rules, and which are aimed at preventing or reducing anxiety or distress, or preventing some dreaded event or situation. These obsessions and/or compulsions cause significant distress, take up a lot of time (an hour or more a day), and interfere with the individual's daily life, including social activities, relationships, and work or school performance. OCD is considered a type of anxiety disorder and can also co-occur with other mental health conditions.

... Type 1a; Jaeken Syndrome GeneReviews/NIH/NCBI/UW entry on Congenital Disorders of ... Glycoprotein metabolism disorders, Membrane transport protein disorders, Congenital disorders of glycosylation). ... "Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular ... "Deficiency of the first mannosylation step in the N-glycosylation pathway causes congenital disorder of glycosylation type Ik ...
... or Leukocyte adhesion deficiency-2 (LAD2) is a type of leukocyte adhesion ... Congenital disorder of glycosylation Leukocyte adhesion deficiency Etzioni A, Harlan JM (2007). "Cell adhesion and leukocyte ... August 2008). "Leukocyte trafficking in a mouse model for leukocyte adhesion deficiency II/congenital disorder of glycosylation ... a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency". Nat. Genet. 28 (1): 73-6. doi: ...
GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview GeneReviews/NIH/NCBI/UW entry on PMM2-CDG (CDG- ... Jaeken J, Matthijs G (2002). "Congenital disorders of glycosylation". Annual Review of Genomics and Human Genetics. 2: 129-51. ... been shown to cause defects in the protein glycosylation pathway which manifest as the congenital disorder of glycosylation ... Congenital Disorder of Glycosylation Type 1a; Jaeken Syndrome v t e (Articles with short description, Short description matches ...
Congenital alterations: Over 40 congenital disorders of glycosylation (CGDs) have been reported in humans. These can be divided ... disorders of protein N-glycosylation, disorders of protein O-glycosylation, disorders of lipid glycosylation and disorders of ... Jaeken J (2013). "Congenital disorders of glycosylation". Pediatric Neurology Part III. Handbook of Clinical Neurology. Vol. ... There are three types of glycosylation disorders sorted by the type of alterations that are made to the glycosylation process: ...
Congenital disorder of glycosylation MPI-CDG EBI Database, IPRO16305 Mannose-6-phosphate Isomerase. "1pmi". PDBe. Gao H, Yu Y, ... GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview Mannose-6-Phosphate+Isomerase at the U.S. ... Jaeken J, Matthijs G (2001). "Congenital disorders of glycosylation". Annual Review of Genomics and Human Genetics. 2: 129-51. ... Additionally M6P is an important signaling molecule, especially for transport to lysosomes: disorders affecting MPI activity ...
"Congenital Disorder of Glycosylation, Type It; CDG1T". Online Mendelian Inheritance in Man. 2012-07-11. Preisler N, Cohen J, ... PGM1, PGM2, PGM3, PGM5 Beta-phosphoglucomutase Congenital disorder of glycosylation Exercise intolerance § Low ATP reservoir in ... The disease is both a glycogenosis and a congenital disorder of glycosylation. It is also a metabolic myopathy and an inborn ...
2004). "Deficiency of the first mannosylation step in the N-glycosylation pathway causes congenital disorder of glycosylation ... 2004). "Congenital Disorder of Glycosylation Type Ik (CDG-Ik): A Defect of Mannosyltransferase I". Am. J. Hum. Genet. 74 (3): ... 608540 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K". Johns Hopkins University. Retrieved 2019-05-01. Couto JR, ... Clinically, the deficiency of ALG1 in humans results in ALG1-CDG, a congenital disorder of glycosylation. GRCh38: Ensembl ...
"Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent ... now known as Congenital Disorders of Glycosylation). He helped show that GnTII null mice are excellent models for human CDG-IIa ... His translational/clinical work also included enzymatic discoveries in the complex muscle-eye-brain diseases (e.g. congenital ... muscular dystrophy) associated with defective O-glycosylation. He has published over 160 scientific papers, reviews, and ...
602579 CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B". Johns Hopkins University. Retrieved 2019-04-30. Harms, H. K.; ... MPI-CDG is an autosomal recessive congenital disorder of glycosylation caused by biallelic pathogenic variants in MPI. The ... Articles with short description, Short description matches Wikidata, Autosomal recessive disorders, Congenital disorders of ... MPI-CDG differs from most other described glycosylation disorders due to its lack of central nervous system involvement, and ...
GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview v t e (All articles with dead external links, ... mutations define congenital disorder of glycosylation Ie (CDG-Ie)". The Journal of Clinical Investigation. 105 (2): 191-8. doi: ... "Congenital disorder of glycosylation (CDG) type Ie. A new patient". Journal of Inherited Metabolic Disease. 27 (5): 591-600. ... "Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie". The Journal of ...
... are the cause of congenital disorder of glycosylation type 2K (CDG2K), an autosomal recessive disorder with variable phenotypes ... Congenital disorders of glycosylation are caused by a defect in glycoprotein biosynthesis and are characterized by under- ... "TMEM165 deficiency causes a congenital disorder of glycosylation". American Journal of Human Genetics. 91 (1): 15-26. doi: ... Modification of the Golgi Ca2+ and pH balance could explain the glycosylation defects observed in TMEM165-deficient patients. ...
"Entry - #614921 - CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T - OMIM". omim.org. Retrieved 2023-02-23. Preisler, ... but as a congenital disorder of glycosylation type 1T (CDG1T), affects the phosphoglucomutase enzyme (gene PGM1). ... Phosphoglucomutase 1 deficiency is both a glycogenosis and a congenital disorder of glycosylation. Individuals with the disease ... A glycogen storage disease (GSD, also glycogenosis and dextrinosis) is a metabolic disorder caused by a deficiency of an enzyme ...
Genetic diseases and disorders, Congenital disorders of glycosylation). ... A defective copy of the PMM2 gene is the most common cause of a disease called "congenital disorders of glycosylation" or "PMM2 ... Barone R, Fiumara A, Jaeken J (July 2014). "Congenital disorders of glycosylation with emphasis on cerebellar involvement". ... "Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature". Journal of Inherited ...
Miller BS, Freeze HH (March 2003). "New disorders in carbohydrate metabolism: congenital disorders of glycosylation and their ... The congenital disorder of glycosylation type Ij is caused by mutation in the gene encoding this enzyme. Alternatively spliced ... Newell JW, Seo NS, Enns GM, McCraken M, Mantovani JF, Freeze HH (July 2003). "Congenital disorder of glycosylation Ic in ... GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview v t e (Articles with short description, Short ...
It forms part of a large group of disorders called congenital disorders of glycosylation. It is caused by mutations in the ... Like other congenital disorders of glycosylation, this condition is extremely rare, with (according to OMIM) only 3 un-related ... "KEGG DISEASE: Congenital disorders of glycosylation type II". www.genome.jp. Retrieved 2022-08-17. "SLC35A1-CDG (CDG-IIf) - ... "Entry - #603585 - CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIf; CDG2F - OMIM". www.omim.org. Retrieved 2022-08-17. Willig, T ...
"Congenital Disorders of Glycosylation". NORD (National Organization for Rare Disorders). Retrieved 2019-08-01. "Mito Info". ... Genetic Inborn errors of metabolism Congenital disorder of glycosylation Mitochondrial disorders Peroxisomal disorder Glucose ... Congenital disorders of nervous system, Disorders causing seizures). ... "Cephalic Disorders Fact Sheet , National Institute of Neurological Disorders and Stroke". www.ninds.nih.gov. Retrieved 2019-08- ...
"Congenital disorder of glycosylation type Id: clinical phenotype, molecular analysis, prenatal diagnosis, and glycosylation of ... Defects in this gene have been associated with congenital disorder of glycosylation type Id (CDG-Id) characterized by abnormal ... GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview ALG3 human gene location in the UCSC Genome ... Jaeken J, Carchon H (2004). "Congenital disorders of glycosylation: a booming chapter of pediatrics". Curr. Opin. Pediatr. 16 ( ...
Mutations in this gene have been associated with congenital disorder of glycosylation type Ih (CDG-Ih). Alternatively spliced ... GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview Human ALG8 genome location and ALG8 gene ... 2004). "Clinical and molecular features of three patients with congenital disorders of glycosylation type Ih (CDG-Ih) (ALG8 ... Jaeken J, Carchon H (2004). "Congenital disorders of glycosylation: a booming chapter of pediatrics". Curr. Opin. Pediatr. 16 ( ...
2004). "Abnormal glycosylation of red cell membrane band 3 in the congenital disorder of glycosylation Ig". Pediatr. Res. 54 (2 ... required for protein glycosylation. Mutations in this gene have been associated with congenital disorder of glycosylation type ... GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview Human ALG12 genome location and ALG12 gene ... Jaeken J, Carchon H (2004). "Congenital disorders of glycosylation: a booming chapter of pediatrics". Curr. Opin. Pediatr. 16 ( ...
Jensen H, Kjaergaard S, Klie F, Moller HU (2003). "Ophthalmic manifestations of congenital disorder of glycosylation type 1a". ... 2007). "Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic ... 2006). "The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of ... GDP-mannose is used for synthesis of dolichol-phosphate-mannose, which is essential for N-linked glycosylation and thus the ...
Defects in this gene have been associated with congenital disorder of glycosylation type Ih (CDG-Ii). ALG2 has been shown to ... Jaeken J (2005). "Congenital disorders of glycosylation (CDG): update and new developments". Journal of Inherited Metabolic ... GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview Human ALG2 genome location and ALG2 gene ... Jaeken J, Carchon H (August 2004). "Congenital disorders of glycosylation: a booming chapter of pediatrics". Current Opinion in ...
July 2014). "PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia". ... Mutations in PGM3 are associated to congenital disorder of glycosylation. GRCh38: Ensembl release 89: ENSG00000013375 - Ensembl ...
"Pathogenic Variants in Fucokinase Cause a Congenital Disorder of Glycosylation". American Journal of Human Genetics. 103 (6): ...
It is also known as Congenital disorder of glycosylation 1m. CEDNIK syndrome List of cutaneous conditions RESERVED, INSERM US14 ... March 2007). "A defect in dolichol phosphate biosynthesis causes a new inherited disorder with death in early infancy". Am. J. ... Glycoprotein metabolism disorders, Rare diseases, All stub articles, Dermatology stubs). ...
CDG1Q or Congenital disorder of glycosylation type 1q) is a rare, non X-linked congenital disorder of glycosylation (CDG) due ... SRD5A3 Congenital disorder of glycosylation Kahrizi syndrome, a syndrome caused by a mutation in this gene "SRD5A3-CDG (CDG-Iq ... It is one of over 150 documented types of Congenital disorders of Glycosylation. Like many other CDGs, SRD5A3 is ultra-rare, ... Jaeken, Jaak; Lefeber, Dirk (18 May 2020). "SRD5A3 defective congenital disorder of glycosylation: clinical utility gene card ...
GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview v t e (Articles with short description, Short ... Defects are associated with congenital disorder of glycosylation type 1N. Flippase GRCh38: Ensembl release 89: ENSG00000163933 ... "Human RFT1 deficiency leads to a disorder of N-linked glycosylation". Am. J. Hum. Genet. 82 (3): 600-6. doi:10.1016/j.ajhg. ...
Eklund EA, Sun L, Yang SP, Pasion RM, Thorland EC, Freeze HH (Jan 2006). "Congenital disorder of glycosylation Ic due to a de ... GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview Human ALG6 genome location and ALG6 gene ... Mutations in this gene are associated with congenital disorders of glycosylation type Ic. GRCh38: Ensembl release 89: ... "A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia ...
GeneReviews/NCBI/NIH/UW entry on Congenital Disorders of Glycosylation Overview This article incorporates text from the United ... Defects can be associated with Congenital disorder of glycosylation type IIc. Solute carrier family EamA GRCh38: Ensembl ... a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency". Nat Genet. 28 (1): 73-6. doi: ...
Mutations in this gene are associated with congenital disorder of glycosylation. GRCh38: Ensembl release 89: ENSG00000136908 - ... defective N-linked glycosylation and deficient O-mannosylation of α-dystroglycan. Dol-P-Man is synthesized from GDP-mannose and ...
"Mutations in STT3A and STT3B cause two congenital disorders of glycosylation". Hum. Mol. Genet. 22 (22): 4638-45. doi:10.1093/ ... "Phenotypic Heterogeneity in a Congenital Disorder of Glycosylation Caused by Mutations in STT3A" (PDF). J. Child Neurol. 32 (6 ... Ruiz-Canada C, Kelleher DJ, Gilmore R (January 2009). "Cotranslational and posttranslational N-glycosylation of polypeptides by ... Malaby HL, Kobertz WR (August 2014). "The middle X residue influences cotranslational N-glycosylation consensus site skipping ...
Congenital Disorder of Glycosylation Type 1a; Jaeken Syndrome GeneReviews/NIH/NCBI/UW entry on Congenital Disorders of ... Glycoprotein metabolism disorders, Membrane transport protein disorders, Congenital disorders of glycosylation). ... "Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular ... "Deficiency of the first mannosylation step in the N-glycosylation pathway causes congenital disorder of glycosylation type Ik ...
... congenital disorder of glycosylation is an inherited condition that often affects the heart but can also involve other body ... DOLK-congenital disorder of glycosylation (DOLK-CDG, formerly known as congenital disorder of glycosylation type Im) is an ... medlineplus.gov/genetics/condition/dolk-congenital-disorder-of-glycosylation/ DOLK-congenital disorder of glycosylation. ... Severe, fatal multisystem manifestations in a patient with dolichol kinase-congenital disorder of glycosylation. Mol Genet ...
... into disorder of protein N-glycosylation, disorder of protein O-glycosylation, disorder of multiple glycosylation, and disorder ... Congenital disorder of glycosylation. Disease definition A fast growing group of inborn errors of metabolism characterized by ... This group is comprised of phenotypically diverse disorders affecting multiple systems including the central nervous system, ... defective activity of enzymes that participate in glycosylation (modification of proteins and other macromolecules by adding ...
Congenital Hyperinsulinism: Isaacs and Levis Story. When a rare disorder was diagnosed in two of their children, the Linares ...
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience ...
Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience This item appears in the following Collection ...
... Purpose:. Qualitative interpretation of sialotransferrin profiles in the ...
congenital disorder of glycosylation Ix congenital disorder of glycosylation type IIa congenital disorder of glycosylation type ... congenital disorder of glycosylation ... PMM2-congenital disorder of glycosylation (PMM2-CDG, also known as congenital disorder ... congenital disorder of glycosylation ... Congenital disorder of glycosylation type 2k (732252005); Congenital disorder of ... glycosylation, disorders of lipid glycosylation and disorders of ... Jaeken J (2013). "Congenital disorders of glycosylation". ...
... congenital-disorder-of-glycosylation-type-ib [meta_description] => [meta_keywords] => [meta_title] => [quantity_discount] => 0 ... Congenital disorder of glycosylation, type IB [description] => [description_short] => [quantity] => 0 [minimal_quantity] => 1 [ ...
The Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC) is part of the Rare Diseases Clinical Research ... trained professionals who have made a commitment to patient-oriented research in the Congenital Disorders of Glycosylation (CDG ... the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child ...
CDG2K is an autosomal recessive disorder with a variable phenotype. Affected individuals show psychomotor retardation and ... Congenital disorder of glycosylation with hepatic involvement*TMEM165-congenital disorder of glycosylation ... Congenital disorder of glycosylation type 2k (732252005); Congenital disorder of glycosylation type IIk (732252005); TMEM165- ... transmembrane protein 165 congenital disorder of glycosylation (732252005); Transmembrane protein 165 congenital disorder of ...
Manchester Science Park, Pencroft Way, Manchester, M15 6SE, United Kingdom ...
... the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three clinical ... CROGVCOG8-congenital disorder of glycosylation. *CROGVCongenital disorder of deglycosylation*CROGVCongenital disorder of ... CROGVCongenital disorder of glycosylation*CROGVALG1-congenital disorder of glycosylation ... PMM2-congenital disorder of glycosylation (PMM2-CDG, also known as congenital disorder of glycosylation type Ia) is an ...
The liver in congenital disorders of glycosylation: Ultrastructural features. Theodore C. Iancu, Muhammad Mahajnah, Irena Manov ... Dive into the research topics of The liver in congenital disorders of glycosylation: Ultrastructural features. Together they ...
Congenital Disorders of Glycosylation (CDG). Rina Bogdanovic [06:10] And your work has very thoroughly focused on Congenital ... we would define that as a Congenital Disorder of Glycosylation. And, in fact, by looking at glycosylation, you can begin to ... his lab was involved in the identification of a number of Congenital Disorders of Glycosylation. Today nearly 170 disorders ... And the other one, of course, is the Frontiers of Congenital Disorders Glycosylation Consortium in the US, you get those on ...
... patients and families on congenital disorders of glycosylation. ... Disorders of N-linked Glycosylation. *Disorders of O-linked ... Publications / Defining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases ... Defining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases. ... Biallelic pathogenic variants in PGAP3 cause a rare glycosylphosphatidyl-inositol biogenesis disorder, PGAP3-CDG. This ...
Clinical and pathological heterogeneity of a congenital disorder of glycosylation manifesting as a myasthenic/myopathic ... identify an homozygous mutation of ALG2 that is related to congenital muscle weakness disorders. The Pippin Prep was used in ...
Genomic disorders and inherited multi-system disorders Abstract. Congenital disorders of glycosylation (CDG) are a large group ... A compound heterozygous mutation in DPAGT1 results in a congenital disorder of glycosylation with a relatively mild phenotype. ... Glycostation disorders; IGMD 4: Glycostation disorders; NCMLS 6: Genetics and epigenetic pathways of disease DCN MP - ... of recessive multisystem disorders caused by impaired protein or lipid glycosylation. The CDG-I subgroup is characterized by ...
... we are studying an inherited condition known as Congenital Disorders of Glycosylation, at GGCs Research Division. Discover how ... Research on Congenital Disorders of Glycosylation (CDGs). Research on Congenital Disorders of Glycosylation (CDGs). GGCs ... Research Division actively studies a group of inherited diseases called the Congenital Disorders of Glycosylation or CDG. These ... Once thought to be very rare, more and more CDG types that affect the different glycosylation pathways in the cell are being ...
Congenital Disorder of Glycosylation Type 1a (PMM2-CDG) and our test PMM2-CDG is a rare genetic disorder that affects the ... Congenital Disorder of Glycosylation Type 1a (PMM2-CDG) Cystic Fibrosis D-Bifunctional Protein Deficiency Dihydrolipoamide ... Phenylketonuria and Related Disorders and our test PKU is part of a spectrum of related genetic disorders. These disorders are ... Zellweger Spectrum Disorder (PEX1-Related) and our test ZSS is a group of rare genetic disorders. The form of ZSS covered by ...
Congenital disorder of glycosylation, type IIy MedGen: C5774294 OMIM: 620200 GeneReviews: Not available ...
N2 - Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective therapies are ... AB - Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective therapies are ... Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective therapies are ... abstract = "Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective ...
Hypoglycosylation is the hallmark of a group of rare genetic diseases called congenital disorders of glycosylation (CDG). These ... Keywords: N-glycans; congenital disorders of N-glycosylation; hemostasis; megakaryopoiesis; platelets; thrombosis. ... deficient N-glycosylation of platelet-derived molecules and discuss the involvement of platelets in the congenital disorders of ... Defects in N-glycosylation and O-glycosylation constitute the largest CDG groups. Clotting and anticlotting factor defects as ...
... is still the method of choice for diagnosis of congenital disorders of glycosylation (CDG). An abnormal glycosylation is also a ... is still the method of choice for diagnosis of congenital disorders of glycosylation (CDG). An abnormal glycosylation is also a ... congenital disorder of glycosylation (CDG); liver transplantation; serum transferrin isoelectrofocusing. ... Pediatric Liver Disease Patients and Secondary Glycosylation Abnormalities Front Pediatr. 2021 Jan 13;8:613224. doi: 10.3389/ ...
Congenital disorder of glycosylation, type Ia. Phosphomannomutase-2 (PMM2; 601785); autosomal recessive ... X-linked congenital ataxia: a clinical and genetic study. Am J Med Genet. 2000 May 1. 92(1):53-6. [QxMD MEDLINE Link]. ... An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology. 2001 Oct 23. 57(8):1499-502. [QxMD ... X-linked nonprogressive congenital cerebellar hypoplasia: clinical description and mapping to chromosome Xq. Ann Neurol. 1996 ...
Congenital disorder of glycosylation, type Ia. Phosphomannomutase-2 (PMM2; 601785); autosomal recessive ... X-linked congenital ataxia: a clinical and genetic study. Am J Med Genet. 2000 May 1. 92(1):53-6. [QxMD MEDLINE Link]. ... An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology. 2001 Oct 23. 57(8):1499-502. [QxMD ... X-linked nonprogressive congenital cerebellar hypoplasia: clinical description and mapping to chromosome Xq. Ann Neurol. 1996 ...
SLC35A2-Congenital Disorder of Glycosylation (SLC35A2-CDG) Alternative Names: Congenital Disorder of Glycosylation Type Iim ( ... Frontiers in Congenital Disorders of Glycosylation (FCDGC). Learn More from the Consortium ... Disease Category: Congenital Disorders of Glycosylation A rare, X-linked dominant, inherited condition caused by an abnormal ... All Diseases > SLC35A2-Congenital Disorder of Glycosylation. Disease Categories. ALS and Related Disorders. Brain Vascular ...
PMM2-Congenital Disorder of Glycosylation (PMM2-CDG) Alternative Names: Congenital Disorder of Glycosylation Type Ia; Jaeken ... Disease Category: Congenital Disorders of Glycosylation The most common, yet rare, congenital disorder of glycosylation. ... Frontiers in Congenital Disorders of Glycosylation (FCDGC). Learn More from the Consortium ... Funds research for congenital disorders of glycosylation (CDG), advocates for screening, raises awareness, and assists families ...
Society of Inherited Metabolic Disorders. Salt Lake City, UT, USA. 2015. Congenital Disorders of Glycosylation: a Sweet Branch ... Congenital Disorders of Glycosylation, A Sweet Branch of Neurometabolics. NYU School of Medicine Child Neurology Grand Rounds. ... Frontiers in Congenital Disorders of Glycosylation - Natural History Project. 4th World Conference on CDG. Lisbon, Portugal. ... Congenital disorders of glycosylation.. 30740408 Annals of translational medicine, 2018 Dec. : 6(24)477 PMCID:PMC6331365 ...
  • Three CDG subtypes PMM2-CDG, PMI-CDG, ALG6-CDG can cause congenital hyperinsulinism with hyperinsulinemic hypoglycemia in infancy. (wikipedia.org)
  • PMM2-CDG, the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three clinical stages: infantile multisystem, late-infantile and childhood ataxia-intellectual disability, and adult stable disability. (beds.ac.uk)
  • A genetically heterogeneous group of heritable disorders resulting from defects in protein N-glycosylation. (lookformedical.com)
  • Congenital disorders of glycosylation (CDGs) are a genetically heterogeneous group of autosomal recessive disorders caused by enzymatic defects in the synthesis and processing of asparagine (N)-linked glycans or oligosaccharides on glycoproteins. (beds.ac.uk)
  • The CDG-I subgroup is characterized by protein N-glycosylation defects originating in the endoplasmic reticulum. (ru.nl)
  • These rare diseases are caused by defects in enzymes and proteins responsible for adding sugars onto proteins and lipids, a process known as glycosylation. (ggc.org)
  • GGC researchers are working to identify the transcriptome and protein changes that are most sensitive to global defects in glycosylation. (ggc.org)
  • Defects in N-glycosylation and O-glycosylation constitute the largest CDG groups. (nih.gov)
  • Hypoglycemia associated with elevated insulin levels makes certain disorders unlikely, such as defects in gluconeogenesis, free fatty acid synthesis and ketogenesis, growth hormone deficiency, and cortisol deficiency. (medscape.com)
  • CDG disorders result from enzyme defects in the post-translational glycosylation of proteins and are associated with developmental delay, dysmorphic features, mental retardation, neurological deficits, and enteropathy. (icnapedia.org)
  • In the subgroup with 'purely' acquired causes (N = 80) strabismus (88% versus 64%), pale optic discs (65% versus 27%) and visual field defects (72% versus 30%) could be observed more frequent than in the subgroup with 'purely' genetic disorders (N = 28). (medscape.com)
  • The other signs and symptoms of DOLK -CDG are likely due to the abnormal glycosylation of additional proteins in other organs and tissues. (medlineplus.gov)
  • Their team is investigating how abnormal glycosylation causes the tissue-specific symptoms of this and other related CDG. (ggc.org)
  • An abnormal glycosylation is also a known phenomenon in adult liver disease patients. (nih.gov)
  • A rare, X-linked dominant, inherited condition caused by an abnormal enzyme disrupting glycosylation. (rarediseasesnetwork.org)
  • A congenital disorder of glycosylation (previously called carbohydrate-deficient glycoprotein syndrome) is one of several rare inborn errors of metabolism in which glycosylation of a variety of tissue proteins and/or lipids is deficient or defective. (wikipedia.org)
  • This compound is critical for a process called glycosylation, which attaches groups of sugar molecules (oligosaccharides) to proteins. (medlineplus.gov)
  • Glycosylation changes proteins in ways that are important for their functions. (medlineplus.gov)
  • A fast growing group of inborn errors of metabolism characterized by defective activity of enzymes that participate in glycosylation (modification of proteins and other macromolecules by adding and processing of oligosaccharide side chains). (orpha.net)
  • However, N-glycosylation of platelet proteins has been poorly investigated in CDG. (nih.gov)
  • Many people with genetic brain disorders fail to produce enough of certain proteins that influence brain development and function. (medlineplus.gov)
  • All stem from dysfunctional N -glycosylation of proteins. (medscape.com)
  • Isoelectric focusing and high-resolution mass spectrometry analyses of serum transferrin revealed glycosylation profiles that are consistent with a CDG-I defect. (ru.nl)
  • Isoelectric focusing (IEF) of serum transferrin (Tf) is still the method of choice for diagnosis of congenital disorders of glycosylation (CDG). (nih.gov)
  • Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation, Serum. (icnapedia.org)
  • Deficiencies in the genes involved in N-linked glycosylation constitute the molecular background of most CDGs. (wikipedia.org)
  • Dr. Lam's clinical and research interest is in congenital disorders of glycosylation (CDGs). (seattlechildrens.org)
  • Multiple abnormalities refer to the presence of two or more medical conditions or disorders in an individual. (lookformedical.com)
  • Common additional features found in this disorder included brain malformations, behavioral abnormalities, cleft palate, and characteristic facial features. (cdghub.com)
  • Disorders that result from defective glycogenolysis in the liver lead to hypoglycemia within a few hours of fasting. (medscape.com)
  • Rare, autosomal recessive disorder caused by deficiency of the beta 2 integrin receptors (RECEPTORS, LEUKOCYTE-ADHESION) comprising the CD11/CD18 family of glycoproteins. (lookformedical.com)
  • Promotes awareness of congenital disorders of glycosylation (CDG) and NGLY1-deficiency, provides resources, and funds scientific research. (rarediseasesnetwork.org)
  • TMEM165-CDG is a form of congenital disorders of N-linked glycosylation characterized by a psychomotor delay-dysmorphism (pectus carinatum, dorsolumbar kyphosis and severe sinistroconvex scoliosis, short distal phalanges, genua vara, pedes planovalgi syndrome) with postnatal growth deficiency and major spondylo-, epi-, and metaphyseal skeletal involvement. (orpha.net)
  • Researchers at SPI (DMTS) have identified by mass spectrometry and bioinformatics analysis several biomarkers linked to the creatine transporter deficiency disorder (CTD) using two original models : mice with the clinical characteristics of CTD subjects and brain organoids derived from CTD patient cells. (cea.fr)
  • Leukocyte adhesion deficiency II may be classified as one of the congenital disorders of glycosylation (CDG), a rapidly expanding group of metabolic syndromes with a wide symptomatology and severity. (medscape.com)
  • Thus, patients with this type of leukocyte adhesion deficiency manifest both severe bacterial infections and bleeding disorder. (medscape.com)
  • Carbohydrate metabolism, inborn errors refer to genetic disorders that affect the body's ability to properly process carbohydrates, leading to various metabolic disorders. (lookformedical.com)
  • Overview of disorders of glycogen metabolism. (springer.com)
  • Kelly A, Stanley CA. Disorders of glutamate metabolism. (springer.com)
  • Disorders of fat metabolism result in the unavailability of free fatty acids and ketones as alternative fuels. (medscape.com)
  • Biochemical genetic testing and newborn screening are essential laboratory services for the screening, detection, diagnosis, and monitoring of inborn errors of metabolism or inherited metabolic disorders. (cdc.gov)
  • Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. (genomeweb.com)
  • However, in persons with West syndrome or hydrocephalus, it might be impossible to unravel whether CVI is caused by the seizure disorder or increased intracranial pressure or by the underlying disorder (that in itself can be acquired or genetic). (medscape.com)
  • NMNAT1 RD3 RDH12 RPGRIP1 SPATA7 TULP1 USP45 Leber congenital amaurosis usually has an autosomal recessive pattern of inheritance. (nih.gov)
  • The Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). (rarediseasesnetwork.org)
  • GGC's Research Division actively studies a group of inherited diseases called the Congenital Disorders of Glycosylation or CDG. (ggc.org)
  • Hypoglycosylation is the hallmark of a group of rare genetic diseases called congenital disorders of glycosylation (CDG). (nih.gov)
  • Congenital Disorders of Glycosylation (CDG) are a large family of rare genetic diseases for which effective therapies are almost nonexistent. (unl.pt)
  • She is the site principal investigator and lead of the natural history for the Frontiers in Congenital Disorders of Glycosylation Consortium, a member of the Rare Diseases Clinical Research Network. (seattlechildrens.org)
  • Strong collaborative links exist in epilepsy, neuroimaging and the recently established MRC Neuromuscular Diseases Centre , which promotes collaborative research on therapy for adults and children with neuromuscular disorders. (gosh.nhs.uk)
  • Other disorders are inherited, which means that a mutated gene or group of genes is passed down through a family. (medlineplus.gov)
  • Biallelic pathogenic variants in PGAP3 cause a rare glycosylphosphatidyl-inositol biogenesis disorder, PGAP3-CDG. (cdghub.com)
  • But genetic variants for a number of the most severe yet prevalent disorders can be challenging to detect by NGS assays. (thermofisher.com)
  • The aim of this study was to characterize glycosylation disturbances in pediatric patients with primary liver disease. (nih.gov)
  • Clinical, biochemical and genetic characteristics of MOGS-CDG: a rare congenital disorder of glycosylation. (seattlechildrens.org)
  • Transferrin glycosylation patterns may normalize so repeat testing is warranted in patients with significant clinical suspicion [1] . (icnapedia.org)
  • Available at https://www.ninds.nih.gov/health-information/disorders/olivopontocerebellar-atrophy . (medscape.com)
  • Collaborators at the King Faisal Specialist Hospital and the Kink Abdulaziz City for Science and Technology, Saudi Arabia, identify an homozygous mutation of ALG2 that is related to congenital muscle weakness disorders. (sagescience.com)
  • DOLK -congenital disorder of glycosylation ( DOLK -CDG, formerly known as congenital disorder of glycosylation type Im) is an inherited condition that often affects the heart but can also involve other body systems. (medlineplus.gov)
  • In this review, we highlight normal and deficient N-glycosylation of platelet-derived molecules and discuss the involvement of platelets in the congenital disorders of N-glycosylation. (nih.gov)
  • The entire spectrum of cerebellar ocular motility disorders can occur in persons with OPCA. (medscape.com)
  • Fukuyama congenital muscular dystrophy (FCMD) is one of the congenital muscular dystrophies, showing central nervous system (CNS) and ocular lesions, in addition to muscular dystrophy. (intechopen.com)
  • Some CDG subtypes, like SSR4-CDG 1y, have been classified as connective tissue disorders. (wikipedia.org)
  • there are many types and subtypes, and other disorders may have overlapping phenotypes. (arupconsult.com)
  • CDG2K is an autosomal recessive disorder with a variable phenotype. (nih.gov)
  • Congenital disorders of glycosylation (CDG) are a large group of recessive multisystem disorders caused by impaired protein or lipid glycosylation. (ru.nl)
  • Patients with CDG have multisystem complications reflecting the central importance of glycosylation to the development and maintenance of most major organ systems in the human body. (ggc.org)
  • The numerous entities in this group are subdivided, based on the synthetic pathway affected, into disorder of protein N-glycosylation, disorder of protein O-glycosylation, disorder of multiple glycosylation, and disorder of glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation. (orpha.net)
  • 3 g of protein/day due to a glomerular disorder plus edema and hypoalbuminemia. (msdmanuals.com)
  • All consultants are actively involved in research focusing on improving the diagnosis and treatment of metabolic disorders of childhood. (gosh.nhs.uk)
  • These recommendations are intended for laboratories that perform biochemical genetic testing to improve the quality of laboratory services and for newborn screening laboratories to ensure the quality of laboratory practices for inherited metabolic disorders. (cdc.gov)
  • During glycosylation, sugars are added to dolichol phosphate in order to build the oligosaccharide chain. (medlineplus.gov)
  • Provides support for career development of biochemically trained professionals who have made a commitment to patient-oriented research in the Congenital Disorders of Glycosylation (CDG) and who have the potential to develop into productive preclinical investigators. (rarediseasesnetwork.org)
  • The investigators are conducting a natural history study of patients with congenital disorders of glycosylation (CDG). (rarediseasesnetwork.org)
  • Once thought to be very rare, more and more CDG types that affect the different glycosylation pathways in the cell are being identified each year. (ggc.org)
  • A genetic brain disorder is caused by a variation or a mutation in a gene. (medlineplus.gov)
  • Some genetic brain disorders are due to random gene mutations or mutations caused by environmental exposure, such as cigarette smoke. (medlineplus.gov)
  • FCDGC is funded under grant number U54NS115198 as a collaboration between NCATS, the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the Office of Dietary Supplements (ODS). (rarediseasesnetwork.org)
  • National Institute of Neurological Disorders and Stroke. (medscape.com)
  • The RDCRN websites are hosted by the network's Data Management and Coordinating Center at Cincinnati Children's Hospital Medical Center, which is funded by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS) under grant number TR002818. (rarediseasesnetwork.org)
  • The Estimated Prevalence of N-Linked Congenital Disorders of Glycosylation Across Various Populations Based on Allele Frequencies in General Population Databases. (cdc.gov)
  • In today's multiethnic society, some genetic disorders previously thought to be confined to specific ethnic groups are increasingly being found in broader populations. (thermofisher.com)
  • Congenital disorders of glycosylation are sometimes known as CDG syndromes. (wikipedia.org)
  • 5] Severe cases of congenital HI may be unresponsive to either diazoxide or octreotide and require intensive management with tube feedings, near-total pancreatectomy, or partial pancreatectomy. (medscape.com)
  • Whole genome and exome sequencing of monozygotic twins with trisomy 21, discordant for a congenital heart defect and epilepsy. (genomeweb.com)
  • This group is comprised of phenotypically diverse disorders affecting multiple systems including the central nervous system, muscle function, immunity, endocrine system, and coagulation. (orpha.net)
  • She is also a member of the medical advisory committee of CDG-Care, a patient advocacy group for individuals with congenital disorders of glycosylation. (seattlechildrens.org)
  • A patient-led infrastructure for research, awareness, and education for Congenital Disorders of Glycosylation. (rarediseasesnetwork.org)
  • Funds research for congenital disorders of glycosylation (CDG), advocates for screening, raises awareness, and assists families. (rarediseasesnetwork.org)
  • NGS enables rapid carrier screening research across the broadest range of disorders, crossing ancestries and geographic regions, with a scalable, cost-effective solution. (thermofisher.com)